RJuro/neuro_patents · Datasets at Hugging Face

appln_id int64 7.41k 576M	appln_filing_date stringlengths 10 10	docdb_family_id int64 3.49M 82.2M	granted stringclasses 2 values	appln_abstract stringlengths 120 10k	appln_abstract_lg stringclasses 1 value	appln_title stringlengths 4 567	applt_coun stringlengths 4 289	invt_coun stringlengths 8 347	cpc stringlengths 11 1.62k	ipc sequence	__index_level_0__ int64 25 167k
364,139,576	2011-11-30	46,172,532	N	Embodiments of the invention include apparatus and methods of non-invasively detecting one or more constituents of a target using multiple wavelength photothermal optical coherence tomography.	en	METHODS AND APPARATUS RELATED TO PHOTOTHERMAL OPTICAL COHERENCE TOMOGRAPHY (OCT)	12491225_US,40343710_US,43701923_US,6893329_US	43701923_US,40343710_US,12491225_US	A61B 3/102,A61B 3/12,A61B 5/0066,A61B 5/02007,A61B 5/14551,A61B 5/4064,A61B 5/4233,A61B 5/4238,A61B 5/4255,A61B 5/441,A61B 5/489,A61B 6/03,G01N 21/171,G01N 21/31,G01N 21/314,G01N 21/39,G01N 21/4795,G01N2021/1787,G01N2021/3144	[ "A61B 6/03", "A61B 3/12" ]	74,084
478,400,706	2016-07-14	40,912,907	N	A prophylactic or therapeutic agent for attention deficit/hyperactivity disorder, containing (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as an active ingredient.	en	PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER	5237012_JP	6683591_JP	A61K 31/343,A61K 45/06,A61P 25/00,A61P 25/14,A61P 25/28,A61P 43/00,C07D 307/77,C07D 317/60,C07D 319/18,C07D 491/048	[ "A61K 31/343" ]	108,775
52,801,571	1996-08-06	26,670,272	Y	This invention provides compounds having the structure <IMAGE> wherein m=0-1; and n=0-1 or a pharmaceutically acceptable salt thereof when m and n=0, that are useful as neuroprotective agents.	en	5H,8H-2-oxa-1,3,5,8-tetraaza-cyclopenta[b]-naphthalene-6,7-diones	5238712_US	7631991_US,6742347_US	C07D 498/04	[ "C07D 498/04" ]	44,720
16,283,068	2005-12-15	36,101,698	N	The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aß). Preferred agents include antibodies, e.g., humanized antibodies specific for Aß.	en	AMYLOID BETA ANTIBODIES FOR USE IN IMPROVING COGNITION	228542_US,650610_BM	1308121_US	A61K2039/505,A61P 25/00,A61P 25/28,A61P 43/00,C07K 14/4711,C07K 16/18,C07K2317/24,C07K2317/56,C07K2317/76,C07K2317/77,C07K2317/92	[ "A61K 39/395", "A61P 25/28", "C07K 16/18" ]	16,564
51,259,875	2005-02-10	35,997,056	Y	The present invention relates to materials and methods for treating neurological diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems.	en	Neurological functions	10827549_US	10827549_US	A61K 31/415,A61K 31/4164,A61P 25/00	[ "A61P 25/00", "A61K 31/415", "A61K 31/4164", "A61K 31/425" ]	41,658
24,036,271	2005-01-17	34,856,866	N	The present invention relates to stable sustained-release oral dosage forms of gabapentin, processes for preparation thereof, and uses thereof in treating epilepsy or post herpetic neuralgia.	en	STABLE SUSTAINED-RELEASE ORAL DOSAGE FORMS OF GABAPENTIN AND PROCESS FOR PREPARATION THEREOF	16812530_IN,12568186_IN,29567671_IN,7220204_IN	16812530_IN,12568186_IN,29567671_IN	A61K 9/2009,A61K 9/2013,A61K 9/2018,A61K 9/2027,A61K 9/2054,A61K 31/197	[ "A61K 31/197", "A61K 9/20" ]	23,512
444,534,373	2015-02-26	54,072,167	N	A dynamic social linking system is disclosed for linking a dreamer user with other users that are associated with dreamer user's recollection or analysis of the dreamer user's dreamt content.	en	SYSTEMS AND METHODS FOR DYNAMIC SOCIAL LINKING OF USER RECOLLECTION OF DREAMT CONTENT	51938319_SG	52053156_SG	G06F 3/04842,G06F 3/0488,G06F 16/9535,G06Q 50/01,G16H 10/60,G16H 20/70,H04L 12/6418,H04L 67/10,H04N 21/252,H04N 21/25875,H04N 21/25883,H04N 21/25891,H04N 21/4126,H04N 21/4788,H04N 21/4826	[ "G06F 15/16", "H04L 12/00", "G06F 3/048", "G06F 7/00", "A61B 5/16", "H04N 21/431", "G06F 17/30" ]	95,832
521,265,240	2019-04-23	56,407,021	N	A method to reduce anxiety and emotional stress includes one or a combination of aromatherapy essential oil blends. The blends include combinations which are fruity, floral, earth, and minty.	en	AROMATHERAPY ESSENTIAL OIL COMPOSITIONS FOR REDUCING ANXIETY	72459339_US	72459339_US	A61B 5/055,A61B 5/165,A61K 9/007,A61M 15/08,A61M 21/02,A61M2021/0005,A61M2021/0016,A61M2205/59,A61M2230/06,A61M2230/205	[ "A61M 21/02", "A61B 5/055" ]	133,262
447,734,439	2015-05-19	54,870,114	Y	An object detector includes a bottom-up object hypotheses generation unit; a top-down object search with supervised descent unit; and an object re-localization unit with a localization model.	en	Object detection with Regionlets re-localization	5263709_US	47304653_US,12207411_US	G01B 11/14,G06K 9/6256,G06T 7/77,G06T2207/10024,G06T2207/20081,G06V 10/255,G06V 10/56	[ "G01B 11/14", "G06K 9/62", "G06K 9/00", "G06T 7/00" ]	98,096
42,208,249	2002-02-19	8,179,909	N	A phenylpiperazine derivative of formula (I), namely, 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl- 4H-benzo[1,4]oxazin-3-one mesylate, useful in treating CNS disorders.	en	8'4-'3-(5-fluoro-1H-indol-3-YL)propyl!-1-piperazinyl!-2-methyl-2H-1,4-benzoxazin -3(4H)-one methanesulfonate with high affinity for the dopamine D2 receptor and the seotonin reuptake site	33981877_	16049562_	A61P 25/00,A61P 25/18,A61P 25/22,A61P 25/24,A61P 31/12,A61P 43/00,C07D 413/12,C07D 413/14	[ "A61P 25/00", "A61K 31/538", "A61P 25/18", "C07D 413/12", "A61P 43/00", "A61P 25/22", "A61P 25/24" ]	28,229
4,447,783	1993-08-30	25,472,737	Y	The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.	en	MONOHYDRATE OF 5-(2-(4-(1,2 BENZISOTHIAZOL-3-YL)-1- PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE	6385626_US	13427977_US,16185737_US,13427976_US,13427975_US	A61K 31/405,A61P 25/00,A61P 25/02,A61P 25/18,A61P 25/20,C07D 417/12	[ "A61P 25/18", "C07D 417/14", "A61P 25/20", "A61K 31/495", "A61K 31/425", "C07D 417/12", "A61P 25/00", "A61K 31/496", "A61P 25/02" ]	4,559
420,889,503	2014-02-14	51,297,842	N	This disclosure is in the area of medical diagnostics that provides a method to assist in diagnosis and monitoring the progression of Alzheimer's disease and mild cognitive impairment (MCI).	en	Screening Blood for Protein Biomarkers and Uses Thereof in Alzheimer's Disease and Mild Cognitive Impairment	5332080_US	48480379_US	G01N 33/6896,G01N2333/4709,G01N2333/4737,G01N2333/51,G01N2333/5403,G01N2333/5428,G01N2333/5434,G01N2333/5437,G01N2333/5443,G01N2333/58,G01N2333/70564,G01N2333/775,G01N2800/2821,G01N2800/50,G01N2800/52	[ "G01N 33/543" ]	88,001
52,896,688	1985-02-26	6,229,403	Y	A membrane of substantially non-crosslinked organic polymers which contain ionogenic groups bonded to the polymer chain via an alkylene radical, at intervals of not less than 4 carbon atoms.	en	Membranes of substantially non-crosslinked organic polymers which contain bonded ionogenic groups	5240549_DE	5263304_DE,5423474_DE	B01D 71/82,C08J 5/2218	[ "C08J 5/22", "C25B 13/08", "C08G 85/00", "C08F 8/00", "B01D 71/82", "B01J 47/12" ]	44,889
15,624,399	2002-05-27	23,133,363	Y	An impact-resistant primer coating composition comprising: - at least one non-hydrophilic acrylate monomer; - at least one epoxy monomer; and - at least one photoactivable cationic catalyst.	en	EPOXY/ACRYLATE BASED PRIMER COATING COMPOSITIONS AND THEIR USE IN THE OPTICAL FIELD.	12537361_US,5542774_FR,25595687_US,13096588_US	12537361_US,13096588_US,25595687_US	C08F 283/10,C08L2312/00,C09D 4/00,C09D 133/068,C09D 151/08,Y10S 525/937,Y10T 428/31504,Y10T 428/31507,Y10T 428/31511,Y10T 428/31533,Y10T 428/31551	[ "C09D 4/02", "C08F 283/10", "C09D 7/12", "C09D 4/00", "C09D 163/00", "C09D 133/06", "C09D 151/08", "C09D 5/00" ]	11,912
30,125,161	1997-06-04	15,301,600	N	A receptor type tyrosine kinase-like protein having an Eph family-like structure and seemingly showing dominant negative (variant being dominant) or signal modification and/or amplification.	en	NOVEL HUMAN RECEPTOR TYPE TYROSINE KINASE-LIKE PROTEIN	13367758_JP,5357769_JP	13367758_JP	A61K 38/00,C07K 14/705,C07K 14/71,C12N 9/1205	[ "C12N 9/12", "C12N 15/12", "C07K 14/705", "C07K 14/71", "A61K 38/00" ]	24,596
456,166,593	2014-03-17	55,961,471	Y	The present invention relates to methods and systems for electronic countermeasures, and particularly to methods and systems for electronic countermeasures that employ radar jamming devices.	en	Passive listening pulse adaptive sidelobe canceller	11012464_US	52588718_US,52683685_US,52649413_US	G01S 7/36,H04K 3/20,H04K 3/228,H04K 3/825,H04K2203/32	[ "H04K 3/00", "G01S 7/36" ]	101,133
53,945,415	1992-05-01	27,414,543	Y	This invention describes the preparation and use of anticonvulsant agents. In particular, triazolopyridine compounds are described which have utility in the treatment of epilepsy in mammals.	en	Pharmaceutically active triazolopyridine compounds	5327265_US	6196288_US	C07D 471/04	[ "C07D 471/04" ]	47,625
42,199,383	2000-09-15	10,861,009	N	An isolate peptide having an amino acid sequence of at least 5 amino acids identical to a portion of amino acids 333-355 of the Hepreceptor for example: MREKEELMLRLQDY(p)EEKTKKAERELSEQIQRALQ	en	Regulatory/unfolding peptides of ezrin	13906407_	25811067_	A61K 38/00,A61P 31/00,A61P 31/12,A61P 31/18,A61P 35/00,A61P 37/00,C07K 14/005,C07K 14/4713,C07K 14/705,C12N2740/16122	[ "C07K 14/16", "C07K 7/08", "C07K 7/06", "A61P 35/00", "A61K 38/00", "C07K 14/705", "C07K 14/47", "A61P 31/18", "A61P 31/00", "A61K 38/17" ]	28,051
16,809,185	1990-03-13	23,327,270	Y	A composition containing a polymeric material obtained by interreacting an epoxy-novolak polymer with an organosilicon compound, a radiation sensitive onium salt, and a near U.V. sensitizer.	en	Negative photoresist and use thereof.	11589_US	2875948_US,2875947_US,2537914_US	G03F 7/0758	[ "H01L 21/027", "G03F 7/038", "G03F 7/075", "H01L 21/30", "C08G 59/00", "G03F 7/029", "C08G 59/18", "C08G 59/14", "G03F 7/004" ]	17,866
23,688,589	2004-09-06	29,226,495	N	The present invention relates to a method of measuring pain in an individual, by calculating the percentage ratio of one neurotransmitter to one or more other neurotransmitters, in a sample.	en	TEST	29236681_GB	29236681_GB	G01N 33/94,G01N 33/942	[ "G01N 33/94" ]	23,012
560,608,395	2021-05-06	78,411,918	N	Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.	en	METHODS OF IMPROVING AUTONOMIC IMBALANCE OR SYMPATHETIC IMPAIRMENT BY REGULATING THE STELLATE GANGLION	79707691_US	81834914_US,81910480_US,81825383_US,79620567_US	A61B 18/14,A61B 90/37,A61B2090/378,A61K 9/0019,A61K 31/167,A61K 31/445,A61K 31/573,A61M 16/022,A61M2202/0208,A61M2210/10,A61N 1/05,A61N 5/0622,A61N 7/02,A61N 7/022,A61N2005/0612,A61N2005/0626,A61N2005/073,A61N2007/0021,A61N2007/003,A61N2007/025,A61P 11/00	[ "A61M 16/00" ]	159,756
46,930,194	2008-03-31	39,795,480	Y	The present invention is drawn to treatment of neuropathic pain due to spinal cord injury. In this regard, the present invention discloses methods and composition to treat neuropathic pain.	en	Treatment for neuropathic pain due to spinal cord injury	5979303_US,5264897_US	5979303_US	A61K 31/7052,A61P 29/00	[ "A61K 31/7052", "A61P 29/00", "C12N 15/11" ]	32,930
50,735,858	1989-10-04	26,942,177	Y	A method of electromyographic scanning paravertebral muscles comprising measuring electrical potential across a persons's spinous process bilaterally across segments of the spinous process.	en	Paraspinal electromyography scanning	8045188_US	8045189_US	A61B 5/389	[ "A61B 5/0488" ]	40,600
47,833,812	1993-09-14	8,204,767	Y	The invention relates to the use of p-chloro-N-(2-morpholinoethyl)benzamide in the treatment of anxiety disorders, such as, panic disorders, social phobia and obsessive compulsive disorder,	en	Treatment of anxiety disorders	6280496_CH,6280495_BR	6280498_CH,6280497_BR	A61K 31/535,A61P 25/18,A61P 25/22	[ "A61P 25/18", "C07D 295/12", "A61P 25/22", "A61K 31/5375", "A61K 31/535" ]	36,402
501,675,244	2018-05-18	57,145,011	Y	In another aspect the invention provides the method for supporting of neurological state assessment and neurological rehabilitation, especially within cognitive and/or speech dysfunctions.	en	System and method for supporting of neurological state assessment and for supporting neurological rehabilitation, especially within cognitive and/or speech dysfunction	77840900_PL,77868943_PL	74790434_PL,74680705_PL	A61B 3/113,A61B 3/14,A61B 5/0062,A61B 5/16,A61B 5/163,A61B 5/486,A61B 5/741,A61B 5/7415,A61B 5/7435,A61B 5/7445,A61M 21/00,A61M2021/0027,A61M2021/005,A61M2205/3303,A61M2205/3313,A61M2205/52,G06F 3/04883,G09B 19/04,G10L 13/00,H04N 5/2253,H04N 5/2256,H04N 5/33	[ "A61B 5/00", "A61B 3/14", "H04N 5/33", "G06F 3/0488", "G09B 19/04", "A61M 21/00", "A61B 5/16", "A61B 3/113", "G10L 13/04", "H04N 5/225" ]	121,679
545,068,189	2020-01-02	74,259,533	N	The disclosure relates to systems, methods and programs for geometrically constrained, unsupervised training of convolutional autoencoders on unlabeled images for extracting eye landmarks.	en	GEOMETRICALLY CONSTRAINED, UNSUPERVISED TRAINING OF CONVOLUTIONAL AUTOENCODERS FOR EXTRACTION OF EYE LANDMARKS	79554212_IL	79576162_IL,79650319_IL,79549313_IL,79593309_IL,79673782_US,79720763_IL	G06K 9/6259,G06N 3/04,G06N 3/0454,G06N 3/08,G06N 3/084,G06N 3/088,G06T 7/11,G06T2207/20081,G06T2207/20084,G06T2207/20132,G06V 10/755,G06V 10/82,G06V 40/165,G06V 40/171,G06V 40/19,G06V 40/193	[ "G06T 7/11", "G06N 3/04", "G06N 3/08", "G06K 9/62", "G06K 9/00" ]	149,571
55,223,393	2008-10-14	39,970,874	N	Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3- dimethyiphenyl)ethyl)-1 H-imidazole-2(3H)-thione.	en	TREATMENT OF SENSORIMOTOR DISORDERS WITH 4- ( 1- ( 2, 3 -DIMETHYLPHENYL) ETHYL) -1H-IMIDAZ0LE-2 ( 3H) -THIONE	40162048_US,12475122_US,12475121_US,5763799_US	12475121_US,40162048_US,12475122_US	A61K 31/4174,A61P 1/06,A61P 25/00,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/30,A61P 25/36	[ "A61P 25/18", "A61P 25/16", "A61P 1/06", "A61P 25/24", "A61K 31/4174", "A61P 25/22", "A61P 25/14" ]	52,853
273,396,593	2006-12-04	35,685,952	N	A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent.	en	Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders	8843796_GB,11187447_GB	11187447_GB,8843796_GB	C12Q 1/6883,C12Q2600/158,G01N 33/505,G01N 33/6896,G01N2800/30,G01N2800/52	[ "C12Q 1/68", "C12Q 1/48", "C12Q 1/02" ]	58,877
469,291,507	2016-03-04	56,879,570	N	Cholesterol and desmosterol levels, and the ratio of these levels can be used as a blood biomarker for Alzheimer's disease, frontotemporal lobar degeneration, or dementia with Lewy bodies.	en	BIOMARKER OF DEMENTIA WITH LEWY BODIES	1371538_JP,4165062_JP	55756971_JP,55690493_JP,55701809_JP,55689012_JP	G01N 33/50,G01N 33/92,G01N2800/2814,G01N2800/52	[ "G01N 33/50", "G01N 33/92" ]	103,513
41,139,079	2007-09-28	36,498,804	Y	Kompozicija, apimanti (i) aromatinio poliesterio derva ir (ii) polidiena, kur daugiau negu 20 moliu procentu mineto polidieno mer vienetu turi 1,2 mikrostruktura arba jo hidrinta liekana.	en	DEGUONI SUGERIANTYS POLIESTERIAI SU PRISLOPINTOMIS PAKARTOTINIO PANAUDOJIMO SPALVOMIS	12473441_US	16941990_US,12473444_US,12473442_US	C08C 19/02,C08C 19/44,C08K 5/098,C08L 9/00,C08L 15/00,C08L 19/00,C08L 19/006,C08L 21/00,C08L 53/02,C08L 67/02	[ "C08L 9/00", "C08K 5/00", "C08G 81/00", "C08L 67/00", "C08L 53/00" ]	26,923
522,630,271	2019-05-23	68,613,797	N	Provided herein are methods related to the evaluation of treatment efficacy for neurological disorders. Also provided are methods for evaluating the progression of neurological disorders.	en	METHODS FOR EVALUATION OF TREATMENT AND PROGRESSION OF NEUROLOGICAL DISORDERS	70105132_US	72363999_US	A61K 31/198,A61K 45/06,A61K 49/0004	[ "A61K 49/00" ]	134,240
570,591,113	2021-05-21	78,707,645	N	The present disclosure provides novel gene therapy constructs comprising a PARK2 gene or activating variant and methods of administering to treat Parkinson's Disease or symptoms thereof.	en	GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE	83646797_US	48468815_US	A61K 48/0058,A61K 48/0075,A61P 25/00,C12N 9/104,C12N 15/86,C12N2750/14143,C12Y 203/02	[ "A61K 48/00" ]	165,056
352,599,054	2011-09-29	45,870,889	N	The present invention relates to the use of TNF-α for the treatment of a pain and/or a urinary tract symptom(s) associated with Cronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).	en	Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome	11789145_US	11789145_US	A61K2039/54,A61K2039/545,A61P 13/00,A61P 13/08,A61P 25/00,C07K 16/241,C07K2317/76	[ "A61K 39/395", "A61P 13/08", "A61P 25/00" ]	72,841
50,107,234	1982-03-25	26,924,545	Y	Neuroleptically active cycloalka[4,5]pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein n, R1, R2 and X are as hereinafter set forth, and intermediates therefore are described.	en	Cycloalka[4,5]pyrrolo[2,3-g]isoquinolines	5244394_US	5278373_US,5259436_US	C07D 209/88,C07D 217/04,C07D 471/04	[ "C07D 209/88", "C07D 217/04", "C07D 471/04" ]	39,591
421,097,057	2012-10-15	48,082,779	N	A method of treating a psychiatric or cognitive developmental disorder in a subject, includes administering to the subject a therapeutically effective amount of at least one RXR agonist.	en	RXR AGONIST COMPOUNDS AND METHODS	5233209_US	11265606_US	A61K 9/0014,A61K 31/192,A61K 31/426,A61K 31/433,A61K 31/4418,A61K 31/4436,A61K 45/06,A61P 25/00,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28	[ "A61K 45/06", "A61K 31/4418", "A61K 31/192" ]	88,110
25,475,157	2001-10-31	18,816,639	N	A gene containing a polynucleotide which encodes the amino acid sequence represented by SEQ ID NO:1; and the polynucleotide encoded by this gene. This is a schizophrenia-associated gene.	en	PCA2501 GENE	27872355_JP,12600858_JP,30544466_JP,15431097_JP,27872356_JP	30544466_JP,12600858_JP,27872355_JP,27872356_JP	C07K 14/47	[ "C12N 15/12", "C07K 14/47" ]	24,152
329,268,864	2010-05-17	42,610,065	Y	The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.	en	Methods of treating urogenital-neurological disorders using galanin retargeted endopeptidases	11571851_US,5273163_US,5608081_US	11571851_US,5608081_US	A61K 38/4893,A61K 47/6415,A61P 13/00,A61P 13/08,A61P 13/10,A61P 15/00,A61P 25/00	[ "A61P 13/00", "A61P 13/08", "A61K 38/48", "A61P 13/10", "C12N 9/96", "C07K 14/00", "C12N 9/00", "A61P 25/00", "A61P 15/00" ]	65,169
298,710,234	2009-10-05	43,857,053	Y	A method for administering nerve growth factor to treat cravings is provided. Pharmaceutical compositions for the treatment of cravings comprising nerve growth factor are also provided.	en	Method of treating cravings by administration of nerve growth factor	7594243_US,12456027_US	7594243_US	A61K 38/185,A61P 1/10,A61P 3/00,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36,A61P 43/00	[ "A61P 43/00", "A61K 38/18" ]	61,371
51,143,225	1974-05-17	27,427,885	Y	Compounds of the formulas WHEREIN R1, R2, R3, R4, R5, R6, m and n and X are as hereinafter set forth, ARE DESCRIBED. The compounds of formulas I and Ia are useful as neuroleptic agents.	en	Dibenzo {8 b,f{9 thiepins bearing piperazinyl substitution	5244394_US	6502347_CH,5295726_CH,8311421_CH	C07D 409/14	[ "C07D 409/14" ]	41,376
574,626,822	2021-11-02	56,895,047	N	The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.	en	Anti-Axl Antagonistic Antibodies	55863587_NO,50059101_NO	79635124_NO,79633243_NO,55878807_NO,54692349_NO,12125511_NO,12244288_NO	A61K 45/06,A61K 47/6801,A61K2039/505,A61P 35/00,A61P 35/02,A61P 35/04,A61P 43/00,C07K 16/2863,C07K 16/32,C07K 16/40,C07K2317/24,C07K2317/33,C07K2317/41,C07K2317/76,C07K2317/92,C07K2319/55,G01N 33/573,G01N 33/574,G01N 33/6893,G01N2333/912,G01N2800/7052	[ "C07K 16/28", "A61P 35/00", "A61K 45/06", "A61K 47/68" ]	166,960
567,933,946	2019-10-29	80,442,651	Y	A system which can implement an electronic version of pai gow poker using an electronic gaming system, as well as a physical pai gow game played with physical cards on a physical table.	en	Casino wagering system	72414939_US	54767028_US	G07F 17/3241,G07F 17/3246,G07F 17/3293	[ "G07F 17/32", "G06F 17/00" ]	163,773
48,554,608	2002-07-12	26,890,086	N	A method and method for measuring emotional and cognitive responses to advertising and other forms of communication through the use of facial electromyographic techniques is described.	en	Continuous emotional response analysis with facial EMG	38258122_,38258123_	38258125_US,38258124_US	A61B 5/16,A61B 5/389,A61B 5/6824	[ "A61B 5/16", "A61B 5/0488" ]	37,377
540,542,709	2020-05-07	73,050,887	N	The disclosure provides methods of making and systems comprising a brain organoid operably connected to a controlled device such that the brain organoid controls the controlled device.	en	BRAIN ORGANOID MACHINE INTERFACE	5439802_US	42274766_US	C12M 35/02,C12N 5/0618,C12N2500/38,C12N2501/11,C12N2501/115,C12N2501/13,C12N2501/727,C12N2503/04,C12N2506/02,C12N2506/45,C12N2513/00,C12N2533/90	[ "C12N 5/071", "C12N 5/0793", "G01N 33/50" ]	146,658
53,452,036	1977-04-13	27,260,186	Y	Thieno[1,5]benzodiazepines having useful CNS activity containing the novel tricyclic ring system: <IMAGE> the 10-position being substituted by an amino, preferably a piperazino, group.	en	Thieno-benzodiazepines	5335192_GB	6766189_GB,6257242_GB	C07C 323/00,C07D 333/38,C07D 333/68,Y10T 428/28,Y10T 428/31815	[ "C07D 333/38", "C07D 495/04", "C07D 333/68" ]	46,114
4,436,249	1993-04-21	11,363,050	N	Aminoalcohols N-acyl derivatives useful in the prevention and in the treatment of human and animal pathologies induced by mast cell degranulation following to a peripheral nerve noxa.	en	AMINOALCOHOLS-N-ACYLDERIVATIVES AS THERAPEUTICAL AGENTS AGAINST THE NEUROGENIC ENDONEURAL OEDEMA DEVELOPING AT THE PERIPHERAL NERVE	16405250_IT	13337807_IT,12983509_IT,12983510_IT	A61K 31/16,A61P 25/02	[ "A61P 25/02", "A61K 31/165", "A61K 31/381", "A61K 31/16", "A61K 9/20", "C07D 339/04", "A61K 31/385", "C07D 333/22", "C07C 233/18", "C07C 233/24", "A61K 31/60" ]	4,511
549,327,076	2020-10-22	75,491,947	N	Provided are compositions and methods for detecting and modulating oscillatory patterns within the basolateral amygdala (BLA) for diagnosis and treatment of anxiety related disorders.	en	Compositions and Methods for Treatment of Post-Traumatic Stress Disorder using Closed-Loop Neuromodulation	5211659_US	79713388_US,79680932_US	A61B 5/0006,A61B 5/165,A61B 5/37,A61B 5/374,A61B 5/378,A61B 5/383,A61B 5/4088,A61B 5/4836,A61B 5/7253,A61B2562/0219,A61B2562/0271,A61B2562/029,A61B2576/026,A61N 1/0534,A61N 1/36089,A61N 1/36096,A61N 1/36139,A61N 1/36189,G06F 3/015,G16H 10/20,G16H 20/30,G16H 20/70,G16H 50/20	[ "A61N 1/05", "A61N 1/36" ]	152,309
444,312,702	2015-03-13	50,278,731	Y	Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.	en	Reversible chemoenzymatic labeling of native and fusion carrier protein motifs	5211659_US	51483092_US,51492264_US,8382655_US	C07F 9/65616,C07K 14/195,C07K 14/37,C07K 19/00,C07K2319/00,C07K2319/21,C07K2319/24,C07K2319/60,C12P 21/06,G01N 33/68,G01N2333/245	[ "C07F 9/6561", "C07K 14/37", "G01N 33/68", "C12P 21/06", "C07K 14/195", "C07K 19/00" ]	95,642
545,289,856	2020-07-16	74,343,719	N	A system and method comprising a noninvasive framework utilizing electroencephalography (EEG) to achieve the neural control of a robotic device for continuous random target tracking.	en	Methods and Systems for Noninvasive Mind-Controlled Devices	5210963_US	79683824_US,79692169_US,79714031_US,79584052_US	A61B 5/245,A61B 5/316,A61B 5/369,A61B 5/7264,A61F 2/72,G05B 19/409,G05B2219/36133,G06F 3/015,G09B 5/02,G09B 19/00,G16H 40/67,G16H 50/20,G16H 50/50	[ "G05B 19/409", "A61B 5/00", "G09B 19/00" ]	149,736
365,447,729	2011-09-23	45,874,425	N	The invention provides novel tricyclic compounds of Formula I' that inhibit β -secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.	en	Compounds for treating neurodegenerative diseases	12503500_US	16716228_US,16844918_US,40434602_US	A61K 31/4188,A61P 25/00,A61P 25/28,C07D 491/107,C07D 491/20	[ "C07D 491/147", "C07D 491/12", "A61K 31/352" ]	74,998
4,546,843	1995-08-14	27,403,950	N	The present invention provides the use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the treatment of anxiety and related disorders.	en	COMPOSITION AND METHOD FOR TREATING ANXIETY	5363504_US	13532451_US,5966506_US,13406344_US,16509917_US,16482671_US	A61K 31/00,A61K 31/198,A61K 31/215,A61P 25/20,A61P 25/22,A61P 43/00,C07C 62/38,C07C 229/50,C07C2602/18,C07D 235/02,Y10S 514/811,Y10S 514/82	[ "A61K 31/198", "C07C 229/50", "A61K 45/00", "C07C 62/38", "A61K 31/215", "A61P 43/00", "C07D 235/02", "A61P 25/20", "A61K 31/195", "A61K 31/00", "A61K 31/19" ]	5,158
4,516,007	1994-07-19	22,259,870	N	Transgenic mice with a human interleukin 1.beta. gene is provided. The transgenic mice may be used to evaluate compounds affecting Alzheimer's Disease and other cognitive disorders.	en	TRANSGENIC ANIMAL MODEL FOR COGNITIVE DISORDERS	5329402_US	16494521_US,16494523_US,13476727_US,16309577_US,16494524_US,16494522_US	A01K 67/0278,A01K2207/15,A01K2217/00,A01K2217/05,A01K2217/20,A01K2227/105,A01K2267/03,A01K2267/0318,A01K2267/0368,C07K 14/545,C12N 15/8509,C12N2830/008	[ "C12N 15/09", "C12P 21/02", "C07K 14/545", "C12N 5/10", "A01K 67/027", "C12N 15/85" ]	4,950
48,160,430	2005-06-07	32,732,343	Y	That deep brain stimulation can be used in the treatment of movement disorders and for identifying an area of the brain to be targeted by DBS in the treatment of movement disorders.	en	Deep brain stimulation of the zona incerta	6457781_US,6218536_GB	6218536_GB	A61N 1/36067,A61N 1/36082	[ "A61N 1/18", "A61N 1/00", "A61N 1/36" ]	36,765
4,571,173	1996-04-18	23,673,720	N	The invention provides a method for treating a dyskinesias comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno¢2,3-b!¢1,5! benzodiazepine.	en	METHOD FOR TREATING DYSKINESIAS	5363504_US	16546026_US	A61K 31/551,A61P 25/02,A61P 25/14,A61P 25/20	[ "A61K 31/551", "A61K 31/55", "A61P 25/20", "A61P 25/02", "C07D 409/04" ]	5,328
520,956,671	2019-04-24	68,238,004	N	A digital image capturing and processing system and method having a plurality of intertwined processing planes for the efficient processing of information associated with an image.	en	Reconfigurable 3D Pixel-Parallel Neuromorphic Architecture for Smart Image Sensor	8433808_US	72404599_US,54706683_US,72353722_US,72364079_US	G06V 10/44,G06V 10/94,G06V 10/955,H04N 5/23229,H04N 5/378	[ "G06K 9/00", "G06K 9/46", "H04N 5/232" ]	133,092
25,488,415	2002-10-29	19,146,074	N	A protease specific to ubiquitin occurring in the brain which is useful in studying the molecular mechanism of the expression neuroplasticity and so on and a DNA encoding the same.	en	UBIQUITIN-SPECIFIC PROTEASE OCCURRING IN THE BRAIN AND DNA ENCODING THE SAME	5816899_JP,30551877_JP,10344330_JP	30551877_JP,10344330_JP	C07K 16/40,C12N 9/6472	[ "C07K 16/40", "C12N 15/55", "C12N 15/12", "C12N 9/64" ]	24,263
365,965,228	2012-08-09	46,717,941	N	This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPAl ion channel and/or medical conditions related to TRPAl, such as pain or asthma.	en	INHIBITING TRANSIENT RECEPTOR POTENTIAL ION CHANNEL TRPA1	43915561_US,16791187_US,16536628_US,16635782_US,16813127_US,12998616_US,12569439_US,16930107_US,43915562_US,16901125_US	16536628_US,43915561_US,16813127_US,16635782_US,12569439_US,43915562_US,16930107_US,16791187_US	A61P 11/06,A61P 25/00,A61P 25/04,A61P 29/00,A61P 43/00,C07D 473/08	[ "A61K 31/52", "C07D 473/08", "A61P 25/04" ]	75,505
499,697,032	2018-04-17	54,360,941	Y	The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.	en	Pyridine or pyrimidine derivatives	48393455_US	6647657_CH,56827109_CH	A61K 31/444,A61K 31/506,A61P 25/18,C07D 211/80,C07D 239/24,C07D 401/04,C07D 401/14	[ "C07D 239/24", "C07D 401/14", "A61K 31/506", "A61K 31/444", "C07D 401/04", "C07D 211/80", "A61P 25/18" ]	120,699
16,889,834	1991-02-28	26,296,748	N	A class of spirocyclic piperidine derivatives are selective ligands at sigma recognition sites and are therefore useful in the treatment and/or prevention of psychiatric disorders.	en	SPIROCYCLIC ANTIPSYCHOTIC AGENTS	212218_GB	3035347_GB,3028788_FR	A61K 31/36,A61K 31/445,A61P 25/18,C07D 221/20,C07D 401/06,C07D 405/06	[ "A61K 31/36", "A61P 25/18", "C07D 221/20", "C07D 405/06", "C07D 401/06", "A61K 31/445" ]	18,091
503,809,306	2018-07-30	55,275,018	Y	The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.	en	Pyrazol-pyridine derivatives	48393455_US	56827109_CH,6647657_CH	A61P 25/00,A61P 25/18,A61P 43/00,C07D 401/04,C07D 409/14	[ "C07D 401/04", "C07D 409/14" ]	122,998
53,592,451	1977-06-30	25,107,765	Y	The beta -endorphin analog beta -endorphin (6-31), although lacking the enkephalin moiety i.e., beta -endorphin (1-5) exhibits analgesic activity which is not reversed by naloxone.	en	{62 -Endorphin analog	5244394_US	9421651_US	A61P 25/04,C07K 14/6755,Y10S 514/809	[ "A61P 25/04", "A61K 38/00", "C07K 14/575", "C07K 14/675", "C07K 14/655" ]	46,532
4,419,450	1992-09-25	25,078,150	N	X-8651 K This invention provides N-alkyl-3-phenyl-3- (2-substituted phenoxy)propylamines which are useful to treat neurological disorders associated with norepinephrine imbalance.	en	N-ALKYL-3-PHENYL-3-(2-HALO-SUBSTITUTED PHENOXY) PRN-ALKYL-3-PHENYL-3-(2-HALO-SUBSTITUTED PHENOXY) PROPYLAMINES OPYLAMINES	16260890_US	16189343_US,16394255_US,16189342_US	A61K 31/135,A61P 1/00,A61P 13/00,A61P 13/02,A61P 15/00,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/26,A61P 25/28,A61P 25/30,A61P 39/02,C07C 217/48,C07C 323/20,C07C 323/29	[ "C07C 319/20", "A61P 15/00", "C07C 217/48", "A61P 25/18", "C07C 323/32", "C07C 323/20", "A61P 13/02", "A61P 39/02", "A61P 25/26", "A61K 31/085", "A61P 25/22", "A61P 25/20", "A61P 13/00", "A61P 25/30", "A61K 31/135", "A61P 25/28", "A61P 1/00", "A61P 25/24" ]	4,423
15,955,026	2002-06-03	8,177,622	Y	The initial status, final status and action performed by user are collected as learning samples which are used for deriving and initializing target action to be performed by user.	en	MAN-MACHINE INTERFACE UNIT CONTROL METHOD; ROBOT APPARATUS; AND ITS ACTION CONTROL METHOD	49843067_JP,15554_DE	49148130_DE,49150369_DE,49185169_DE,49220106_JP,49211311_JP,49585397_JP,49650549_JP	B62D 57/02,B62D 57/032,G05B 13/0265,G05B 19/042	[ "B62D 57/02", "A63H 11/00", "B62D 57/032", "G05B 19/042", "G05B 13/02" ]	14,272
15,944,733	2002-02-05	23,016,078	Y	This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.	en	USE OF QUETIAPINE FOR THE TREATMENT OF COCAINE DEPENDENCE	5864_SE	1286744_US	A61K 31/554,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36	[ "A61K 31/554", "A61P 25/34", "A61P 25/32", "A61P 25/36", "A61P 25/30", "C07D 281/16" ]	14,139
53,963,636	1997-06-24	26,717,449	Y	A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.	en	Method for treating Meniere's disease	6331289_US	6229446_US,5267045_US,10343578_US,10343579_US	A61K 31/55	[ "A61K 31/55" ]	47,677
16,373,462	2006-12-05	37,904,362	N	The invention encompasses 2-(N-methyl-propanamine)-3-(2-naphthol) thiophene, a duloxetine hydrochloride impurity, as well as its use as a reference marker and reference standard.	en	2-(N-METHYL-PROPANAMINE)-3-(2-NAPHTOL) THIOPHENE, AN IMPUTITY OF DULOXETINE HYDROCHLORIDE	8477_IL	2108721_IL,2128115_IL,146982_IL,2128113_IL,2128114_IL,2128116_IL	A61P 13/00,A61P 25/24,A61P 29/00,C07D 333/20	[ "A61P 25/24", "A61P 29/00", "A61K 31/38", "C07D 307/52", "A61P 13/00" ]	17,122
16,730,901	1988-08-11	22,203,256	N	Certain amino-2-hydroxypropyloximinoheterocycles are beta -adrenoceptor antagonists useful in the treatment of elevated intraocular pressure, hypertension, angina and arrhythmia.	en	AMINO-2-HYDROXYPROPYLOXIMINO-HETEROCYCLE BETA BLOCKERS	11493_US	2731791_US,2479310_US,2257034_US,2257033_US,2731792_US	A61P 9/12,A61P 25/02,A61P 27/02,A61P 27/06,C07D 333/36,C07D 335/02,C07D 339/00	[ "A61K 31/38", "C07C 251/58", "A61P 27/06", "C07D 495/04", "C07D 337/04", "C07D 335/02", "C07D 333/38", "C07D 495/10", "A61K 31/15", "A61P 27/02", "C07D 333/36", "C07C 67/00", "A61K 31/215", "A61P 9/12", "C07D 339/00", "A61K 31/381", "C07C 239/00", "A61K 31/382", "A61P 25/02", "A61K 31/385" ]	17,701
56,454,987	2006-05-17	37,533,259	N	The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker.	en	METHOD FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE.	11372958_ES	40440769_,40440768_,16913546_ES,40440765_,40440766_,40440767_	C07K 14/4711,C07K 14/705,C12Q 1/6883,C12Q2545/114,C12Q2600/112,C12Q2600/158,G01N 33/50,G01N 33/53,G01N 33/5308,G01N 33/6896,G01N2800/2821	[ "C07K 14/705" ]	54,489
52,005,965	1975-06-05	26,413,683	Y	3-[2-(4-PHENYL-1-PIPERAZINYL)ETHYL]-4H-pyrido[1,2-a]pyrimidin-4-one derivatives have central nervous depressant and hypotensive activities and are useful as major tranquillizers.	en	Pyrido{8 1,2-a{9 pyrimidinone derivatives	5244603_JP	8992928_JP,5933253_JP,7561438_JP,6122567_JP	C07D 471/04	[ "C07D 471/04" ]	43,248
55,425,972	2008-06-04	40,089,060	Y	Apparatus and method for delivering audible, electrical or mechanical tones having a specific characteristic to a human vestibular system to achieve thereby a therapeutic result.	en	Neuromuscular therapeutic device	10815674_US,10815672_US,10815673_US,10815671_US	10815674_US,10815673_US,10815672_US	A61N 1/36036	[ "A61N 1/00", "A61H 1/00" ]	53,197
52,034,934	1984-03-13	26,992,223	Y	A pulmonary training method for persons having COPD involving daily exercise by inhaling through a restricted opening with inspirative resistance less than that producing stress.	en	Pulmonary training method	9016150_US	9016151_US	A63B 23/18	[ "A63B 23/18" ]	43,304
4,747,904	2000-08-01	16,717,834	N	Remedies for neurogenic pains comprising an mGluR1 receptor antagonist for systemic administration. Thus, drugs efficacious in treating various neurogenic pains can be provided.	en	PHARMACEUTICALS FOR NEUROPATHIC PAIN	7329924_JP	13126974_JP,16703972_JP,16703973_JP,13126975_JP,9610565_JP	A61K 31/00,A61K 31/429,A61P 25/00	[ "A61K 31/429", "A61K 31/00", "A61P 25/00" ]	7,138
52,836,790	1976-06-18	24,532,742	Y	N-(4-aminophenyl)-aromatic dicarboximides, e.g. those of the formula <IMAGE> R = alkyl, (hydroxy, alkoxy or alkanolyloxy)-alkyl R' = chloro OR SALTS THEREOF ARE ANTICONVULSANTS.	en	Aromatic dicarboximides	5232729_US	9564250_US,5436061_US	C07D 209/48,C07D 217/24,C07D 307/89,C07D 333/38,C07D 471/04,Y10S 514/96	[ "C07D 209/48", "C07D 217/24", "C07D 333/38", "C07D 307/89", "C07D 471/04" ]	44,777
474,746,084	2015-06-12	54,934,605	Y	The disclosure provides methods of detecting and monitoring brain injury in a test subject comprising analyzing a blood sample from the test subject for increased levels of PrP	en	Methods and kits for detecting brain injury	8044048_CA	53846426_	A61B 5/150022,A61B 5/15003,A61K 39/0007,C07K 14/47,G01N 33/6893,G01N 33/6896,G01N2333/47,G01N2333/70596,G01N2800/28,G01N2800/2828,G01N2800/40,G01N2800/56	[ "G01N 33/53", "C07K 14/47", "A61B 5/15" ]	106,502
45,633,003	2001-10-05	26,931,920	N	Bile-acid conjugates useful for sustained release of L-DOPA, inhibitors of catechol O-methyl transferase and/or inhibitors of L-aromatic amino acid decarboxylase are provided.	en	BILE ACID PRODRUGS OF L-DOPA AND THEIR USE IN THE SUSTAINED TREATMENT OF PARKINSONISM	12474189_US,37049520_US,12491874_US,12614443_US	37049520_US,12614443_US,12491874_US	A61K 38/00,A61K 47/554,A61K 47/64,A61K 47/65,C07K 5/0205	[ "A61K 38/00", "A61K 47/48", "C07K 5/02" ]	30,381
518,721,580	2019-05-20	40,789,289	Y	System and methods related to wagering, such as slot machines and/or other electronic games. Some wagering may relate to market indicators, market lines, and/or stop commands.	en	System and method for slot machine game associated with financial market indicators	5436255_US	70117834_US,72351974_US	G07F 17/32,G07F 17/3227,G07F 17/3244,G07F 17/3262,G07F 17/34	[ "A63F 13/00", "G07F 17/32", "G07F 17/34" ]	131,263
219,970	2003-11-24	32,392,528	Y	The invention provides a waterborne epoxy corrosion resistant primer comprising a waterborne epoxy, a curing agent, and a non-chromate containing corrosion-inhibiting pigment.	en	Chromate free waterborne epoxy corrosion resistant primer	11080_US	339573_US	C09D 5/08,C09D 5/084,C09D 163/00	[ "C09D 5/08", "C09D 7/12", "C09D 163/00", "C09D 5/02", "C09D 163/02", "C09D 5/00", "C09D 177/00" ]	1,207
413,397,189	2011-11-04	46,025,134	N	The present invention relates to a cell-based model useful for identifying molecules that modify intracellular pathways of alpha-synuclein and tau aggregation and degradation.	en	Cell-Based Models of Neurodegenerative Disease	12289087_US,45367273_US,11160493_US,5223267_US,45367275_US,45367274_US,7082996_US	12289087_US,7082996_US,45367274_US,45367275_US,11160493_US,45367273_US	G01N 33/5058,G01N 33/6896	[ "G01N 33/68", "G01N 33/50" ]	83,827
53,446,976	2007-04-11	38,520,579	Y	The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor	en	Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders	5223604_US	8484525_US,5823321_US,8484527_US,8484524_US	A61P 25/00,A61P 25/28,C07D 491/06	[ "C07D 498/04", "A61K 31/538", "A61K 31/5365", "C07D 491/04" ]	46,097
52,785,391	1976-05-26	25,693,196	Y	(+)-(S)-enantiomer of 3-{2-[4-(8-fluoro-10,11-dihydro-2-methyldibenzo[b,f]thiepin-10-yl)-1-p iperazinyl]-ethyl} -2-oxazolidinone, active as a neuroleptic agent, is described.	en	({30 )-(S)-Enantiomer of 3-{55 2-{8 4-(8-fluoro-10,11-dihydro-2-methyl-dibenzo{8 b,f{9 thiepin-10-yl)-1-piperazinyl{9 -ethyl{56 -2-oxazolidinone	5746081_US	5295726_CH	A61K 31/38,C07C 323/00,C07D 337/14	[ "C07D 413/14", "C07D 409/14", "C07D 413/12", "A61K 31/38", "C07D 403/14", "A61K 31/55", "C07D 337/14" ]	44,683
53,354,402	2004-02-03	33,423,057	N	Computerized training apparatus which combines electroencephalograph (EEG) based biofeedback attention training with behavior modification support, coaching support, or both.	en	Systems and methods for behavioral modification and behavioral task training integrated with biofeedback and cognitive skills training	39508482_US	39508483_US,39508484_US,39508485_US	A61B 5/375,G06Q 50/20,G09B 7/02	[ "G06F 17/00", "G06F 15/18", "G06N 5/02", "G06N 5/04" ]	45,866
58,123,712	2007-11-09	39,364,112	N	A hetero-dimeric or hetero-oligomeric receptor, comprising at least one t hyrotropin releasing hormone receptor subunit associated with at least one o rexin receptor subunit.	en	THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS	15085685_AU	40902669_AU,40902668_AU,40902666_AU,40902667_AU	A61P 3/04,A61P 25/00,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28,A61P 43/00,G01N 33/542	[ "C07K 14/72", "G01N 33/566", "A61K 38/22", "C07K 16/28", "G01N 33/74", "G01N 33/78" ]	57,254
53,997,202	1997-07-03	10,796,408	Y	This invention relates to a method of electron spin resonance enhanced magnetic resonance imaging which relies on ex vivo dynamic nuclear polarisation of an MR imaging agent.	en	Nuclear Polarization Enhanced Nuclear Magnetic Resonance Imaaging	5294754_NO,10371320_FI	5969477_DK,5588699_DK,8857106_SE,5601508_SE,10371322_SE,7761484_FI,10371321_GB	G01R 33/282,G01R 33/5601,G01R 33/62	[ "G01N 24/12", "B82B 1/00", "A61B 5/055", "G01R 33/62", "G01R 33/28" ]	47,777
527,281,819	2019-09-05	69,641,779	N	The present disclosure provides methods for diagnosing and determining the disease progression of neurodegenerative disorders in patients using neurophysiological biomarkers.	en	Neurophysiological Biomarkers for Neurodegenerative Disorders	5219515_US	74752170_US,74798571_US	A61B 5/316,A61B 5/389,A61B 5/4082,A61B 5/4088,A61B 5/4842,A61B 5/6824	[ "A61B 5/00", "A61B 5/0488", "A61B 5/04" ]	137,616
45,722,783	2003-11-20	32,329,181	N	Transcranial magnetic stimulation is interleaved with functional brain imaging to examine cortex sensitivity and brain communication and to determine efficacy of medication.	en	METHODS AND SYSTEMS FOR USING TRANSCRANIAL MAGNETIC STIMULATION AND FUNCTIONAL BRAIN MAPPING FOR EXAMINING CORTICAL SENSITIVITY, BRAIN COMMUNICATION, AND EFFECTS OF MEDICATION	37112672_US,37131631_US,10242514_US,37112671_US	37131631_US,37112672_US,37112671_US	G01R 33/4806,G01R 33/4808	[ "A61B 5/055", "G01R 33/48", "A61B" ]	31,869
52,823,299	1985-01-28	10,113,358	Y	Benzodiazepines of formula <IMAGE> wherein R3 is methyl or ethyl and R4 is chlorine or fluorine are useful therapeutic agents for the treatment of neuropsychic disturbances.	en	Method of treating neuropsychic disturbances by benzodiazepine derivatives and composition therefor	5271897_FR	5246427_FR,8271048_FR	A61P 21/02,A61P 25/00,A61P 25/08,A61P 25/20,A61P 25/26,C07D 243/24	[ "A61K 31/55", "A61P 25/08", "A61K 31/551", "A61K 31/5513", "A61K 31/495", "C07D 243/18", "C07D 243/16", "C07D 243/24", "C07D 243/28", "C07D 243/26", "A61P 25/26", "A61P 21/02", "A61P 25/20", "A61P 25/00" ]	44,750
51,943,561	1984-02-02	27,045,759	Y	4-Hydroxy-N-[5-[(substituted hetero)methyl]-3-isoxazolyl]-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides as agents for treating pain in mammals resulting from inflammation.	en	3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides	5233822_US	6210171_US,5471439_US	C07D 261/14,C07D 261/18,C07D 417/12	[ "C07D 261/14", "C07D 417/12", "C07D 261/18" ]	43,098
449,584,270	2014-03-14	51,538,346	Y	EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.	en	EGFR-binding modular recognition domains	12178422_US	9649388_US,11958076_US,10546187_US,7163384_US	A61K 38/00,A61K 45/06,A61K2039/505,A61P 29/00,A61P 35/00,C07K 7/08,C07K 14/435,C07K 16/18,C07K 16/24,C07K 16/28,C07K 16/2848,C07K 16/2863,C07K 16/32,C07K 16/40,C07K2317/31,C07K2317/35,C07K2317/76,C07K2319/00,C12N 9/0002,Y02A 50/30	[ "A61K 38/10", "C07K 16/32", "A61K 39/00", "C07K 16/40", "A61K 45/06", "C07K 7/08", "C07K 19/00", "C12N 9/00", "C07K 16/28", "A61K 38/00", "A61K 39/395", "C07K 16/24", "C07K 14/435", "C07K 16/18" ]	99,174
53,298,596	1977-01-24	24,558,317	Y	Novel 1-hydroxy-3-alkyl-6,7,8,9,10,11-hexahydrodibenz[b,d]oxepins are prepared from cyclohexenyl resorcinol derivatives and are useful as central nervous system depressants.	en	Cyclohexenyl resorcinol derivatives	5255150_US	6314162_US	C07C 39/23,C07C2601/16,C07D 313/10	[ "C07D 313/10", "C07C 39/23" ]	45,719
537,914,188	2020-03-11	70,155,381	N	A method of treating CNS tumors such as gliomas is provided comprising delivering a β-emitting radionuclide containing composition to the tumor via the cerebral vasculature.	en	TREATMENT OF CNS TUMORS	5505141_GB,5218813_US	77886481_US,11572052_US,52622076_US	A61K 9/0019,A61K 51/1251,A61K 51/1255,A61K2121/00,A61P 35/00	[ "A61P 35/00", "A61K 51/12", "A61K 9/00" ]	144,728
274,180,594	2007-08-31	39,157,768	N	Compounds of formula (I). Selectively inhibit production of Abeta(1-42) and hence find use in treatment of diseases associated with deposition of beta-amyloid in the brain.	en	DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS	9090002_US,11250469_US,9090009_US,11250468_US,9090010_US	11250468_US,9090009_US,9090010_US,9090002_US,11250469_US	A61P 25/28,C07D 211/38	[ "C07D 211/38", "A61K 31/445" ]	59,817
450,862,951	2015-09-25	55,583,340	N	Disclosed are compounds, compositions and methods for stopping seizures, including status epilepticus, and are useful for the treatment and prevention of seizure disorders.	en	METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING	5292546_US	6098141_US	A61K 31/05,A61K 31/16,A61K 45/06	[ "A61K 45/06", "A61K 31/05" ]	100,117
420,198,802	2012-07-27	46,581,998	N	A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.	en	COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD1 MAYTANSINOID IMMUNOCONJUGATE AND RITUZIMAB	5271897_FR	47183502_FR,47209462_FR,47283087_FR	A61K 31/537,A61K 39/3955,A61K 39/39558,A61K 47/6803,A61K 47/6849,A61K2039/507,A61P 35/00,A61P 35/02,C07K 16/2803,C07K 16/2887	[ "A61K 47/48", "A61K 39/395", "A61K 31/537" ]	87,506
52,147,844	1996-02-20	32,045,695	Y	A method of making antibodies to hirudin by immunizing with an immunogenic composition containing polymerized hirudin monomers in the absence of carrier protein is taught.	en	Anti-hirudin polyclonal antibodies and their use for the identification, immunopurification and quantitative determination of hirudin	5245423_IT	9103748_IT,7926710_IT,5861859_IT,9103747_IT,9103746_IT	C07K 14/815,C07K 16/38,Y10S 530/855	[ "C07K 16/38", "C07K 14/815" ]	43,534
340,493,256	2011-07-01	45,400,192	N	A chiral synthesis of pyrrolidine compounds en route to seletive neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.	en	CHIRAL SYNTHESIS OF PYRROLIDINE CORE COMPOUNDS EN ROUTE TO NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS	12579331_US,43351681_US,5279165_US	43351681_US,12579331_US	C07D 401/06,C07D 401/12,C07D 493/08	[ "C07B 55/00", "C07D 401/14", "C07D 401/06" ]	71,525
16,682,779	1987-06-23	25,376,501	N	Cyclic and bridged cyclic somatostatin analogs have been found to be effective in the treatment of peripherally mediated pain and are therefore useful as analgesic agents.	en	CYCLIC AND BRIDGED CYCLIC SOMATOSTATIN ANALOGS USEFUL AS ANALGESIC AGENTS	11493_US	2645541_US,2645542_US,2378892_US	A61K 38/31,A61P 25/04	[ "C07K 14/655", "A61K 38/00", "A61K 38/31", "A61K 38/04", "C07K 7/06", "A61P 25/04", "C07K 7/64", "C07K 14/575" ]	17,591
4,031,236	1976-02-17	24,285,695	Y	TRIAZOLOCYCLOALKYLTHIADIAZINE DE,RIVATIVES Novel triazolocycloalkylthiadiazines, their preparation, and use as antisecretory agents and central nervous system depressants.	en	TRIAZOLOCYCLOALKYLTHIADIAZINE DERIVATIVES	15820088_	15832060_	C07D 249/12,C07D 513/04	[ "C07D 513/04", "C07D 249/12", "C07D 249/14" ]	3,280
46,305,165	2005-01-27	35,461,012	Y	Novel BNP variants. The novel BNP variants according to the present invention may optionally be used for diagnosis of a BNP variant-detectable disease as described herein.	en	Brain natriuretic peptide spliced variant	5671065_IL	5671071_GB,5671068_IL,5671072_IL,5671069_IL,5671067_IL,5671070_IL,5671066_IL	G01N 33/74,G01N2800/321,G01N2800/325	[ "G01N 33/53", "C07K 14/705", "C07K 14/435", "G01N 33/74", "A61K 38/17" ]	32,415
53,758,754	1977-10-14	27,172,028	Y	Novel thienotriazolodiazepine derivatives and processes for their preparation are described. These compounds are useful as anticonvulsants, muscle-relaxants and sedatives.	en	Thienotriazolodiazepine derivatives	5244394_US	8632746_AT,5594795_CH,6089165_AT,8469920_CH	C07D 333/36,C07D 495/04,C07D 495/14,Y10S 514/906,Y10S 514/937,Y10S 514/962,Y10S 514/966	[ "C07D 495/04", "C07D 333/36", "C07D 495/14" ]	47,021
337,451,960	2011-04-01	44,079,474	Y	Novel polymorphic forms and salts of 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.	en	Polymorphs and salts	11887758_IT,5859336_IT,11887759_IT,5859335_IT,5219543_IT	11887759_IT,11887758_IT,5859335_IT,5859336_IT	A61K 9/0053,A61K 31/19,A61K 31/192,A61P 25/28,C07B2200/13,C07C 61/40,C07C 229/26,C07C 279/14,C07C2601/02	[ "A61K 31/192", "A61P 25/28", "C07C 61/40" ]	69,801
458,815,708	2014-08-19	52,484,110	N	The invention relates to methods of detecting a genetic variation in a genetic sample from a subject using labeled probes and counting the number of labels in the probes.	en	Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers	60040665_	69285340_,60435032_,63193519_,58426412_	C12Q 1/6809,C12Q 1/6825,C12Q 1/6827,C12Q 1/6837,C12Q 1/6876,C12Q2600/156,C12Q2600/158,C12Q2600/16	[ "G01N 33/53" ]	102,602

364,139,576

2011-11-30

46,172,532

N

Embodiments of the invention include apparatus and methods of non-invasively detecting one or more constituents of a target using multiple wavelength photothermal optical coherence tomography.

en

METHODS AND APPARATUS RELATED TO PHOTOTHERMAL OPTICAL COHERENCE TOMOGRAPHY (OCT)

12491225_US,40343710_US,43701923_US,6893329_US

43701923_US,40343710_US,12491225_US

A61B 3/102,A61B 3/12,A61B 5/0066,A61B 5/02007,A61B 5/14551,A61B 5/4064,A61B 5/4233,A61B 5/4238,A61B 5/4255,A61B 5/441,A61B 5/489,A61B 6/03,G01N 21/171,G01N 21/31,G01N 21/314,G01N 21/39,G01N 21/4795,G01N2021/1787,G01N2021/3144

[ "A61B 6/03", "A61B 3/12" ]

74,084

478,400,706

2016-07-14

40,912,907

N

A prophylactic or therapeutic agent for attention deficit/hyperactivity disorder, containing (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide as an active ingredient.

en

PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER

5237012_JP

6683591_JP

A61K 31/343,A61K 45/06,A61P 25/00,A61P 25/14,A61P 25/28,A61P 43/00,C07D 307/77,C07D 317/60,C07D 319/18,C07D 491/048

[ "A61K 31/343" ]

108,775

52,801,571

1996-08-06

26,670,272

Y

This invention provides compounds having the structure <IMAGE> wherein m=0-1; and n=0-1 or a pharmaceutically acceptable salt thereof when m and n=0, that are useful as neuroprotective agents.

en

5H,8H-2-oxa-1,3,5,8-tetraaza-cyclopenta[b]-naphthalene-6,7-diones

5238712_US

7631991_US,6742347_US

C07D 498/04

[ "C07D 498/04" ]

44,720

16,283,068

2005-12-15

36,101,698

N

The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aß). Preferred agents include antibodies, e.g., humanized antibodies specific for Aß.

en

AMYLOID BETA ANTIBODIES FOR USE IN IMPROVING COGNITION

228542_US,650610_BM

1308121_US

A61K2039/505,A61P 25/00,A61P 25/28,A61P 43/00,C07K 14/4711,C07K 16/18,C07K2317/24,C07K2317/56,C07K2317/76,C07K2317/77,C07K2317/92

[ "A61K 39/395", "A61P 25/28", "C07K 16/18" ]

16,564

51,259,875

2005-02-10

35,997,056

Y

The present invention relates to materials and methods for treating neurological diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems.

en

Neurological functions

10827549_US

A61K 31/415,A61K 31/4164,A61P 25/00

[ "A61P 25/00", "A61K 31/415", "A61K 31/4164", "A61K 31/425" ]

41,658

24,036,271

2005-01-17

34,856,866

N

The present invention relates to stable sustained-release oral dosage forms of gabapentin, processes for preparation thereof, and uses thereof in treating epilepsy or post herpetic neuralgia.

en

STABLE SUSTAINED-RELEASE ORAL DOSAGE FORMS OF GABAPENTIN AND PROCESS FOR PREPARATION THEREOF

16812530_IN,12568186_IN,29567671_IN,7220204_IN

16812530_IN,12568186_IN,29567671_IN

A61K 9/2009,A61K 9/2013,A61K 9/2018,A61K 9/2027,A61K 9/2054,A61K 31/197

[ "A61K 31/197", "A61K 9/20" ]

23,512

444,534,373

2015-02-26

54,072,167

N

A dynamic social linking system is disclosed for linking a dreamer user with other users that are associated with dreamer user's recollection or analysis of the dreamer user's dreamt content.

en

SYSTEMS AND METHODS FOR DYNAMIC SOCIAL LINKING OF USER RECOLLECTION OF DREAMT CONTENT

51938319_SG

52053156_SG

G06F 3/04842,G06F 3/0488,G06F 16/9535,G06Q 50/01,G16H 10/60,G16H 20/70,H04L 12/6418,H04L 67/10,H04N 21/252,H04N 21/25875,H04N 21/25883,H04N 21/25891,H04N 21/4126,H04N 21/4788,H04N 21/4826

[ "G06F 15/16", "H04L 12/00", "G06F 3/048", "G06F 7/00", "A61B 5/16", "H04N 21/431", "G06F 17/30" ]

95,832

521,265,240

2019-04-23

56,407,021

N

A method to reduce anxiety and emotional stress includes one or a combination of aromatherapy essential oil blends. The blends include combinations which are fruity, floral, earth, and minty.

en

AROMATHERAPY ESSENTIAL OIL COMPOSITIONS FOR REDUCING ANXIETY

72459339_US

A61B 5/055,A61B 5/165,A61K 9/007,A61M 15/08,A61M 21/02,A61M2021/0005,A61M2021/0016,A61M2205/59,A61M2230/06,A61M2230/205

[ "A61M 21/02", "A61B 5/055" ]

133,262

447,734,439

2015-05-19

54,870,114

Y

An object detector includes a bottom-up object hypotheses generation unit; a top-down object search with supervised descent unit; and an object re-localization unit with a localization model.

en

Object detection with Regionlets re-localization

5263709_US

47304653_US,12207411_US

G01B 11/14,G06K 9/6256,G06T 7/77,G06T2207/10024,G06T2207/20081,G06V 10/255,G06V 10/56

[ "G01B 11/14", "G06K 9/62", "G06K 9/00", "G06T 7/00" ]

98,096

42,208,249

2002-02-19

8,179,909

N

A phenylpiperazine derivative of formula (I), namely, 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl- 4H-benzo[1,4]oxazin-3-one mesylate, useful in treating CNS disorders.

en

8'4-'3-(5-fluoro-1H-indol-3-YL)propyl!-1-piperazinyl!-2-methyl-2H-1,4-benzoxazin -3(4H)-one methanesulfonate with high affinity for the dopamine D2 receptor and the seotonin reuptake site

33981877_

16049562_

A61P 25/00,A61P 25/18,A61P 25/22,A61P 25/24,A61P 31/12,A61P 43/00,C07D 413/12,C07D 413/14

[ "A61P 25/00", "A61K 31/538", "A61P 25/18", "C07D 413/12", "A61P 43/00", "A61P 25/22", "A61P 25/24" ]

28,229

4,447,783

1993-08-30

25,472,737

Y

The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.

en

MONOHYDRATE OF 5-(2-(4-(1,2 BENZISOTHIAZOL-3-YL)-1- PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE

6385626_US

13427977_US,16185737_US,13427976_US,13427975_US

A61K 31/405,A61P 25/00,A61P 25/02,A61P 25/18,A61P 25/20,C07D 417/12

[ "A61P 25/18", "C07D 417/14", "A61P 25/20", "A61K 31/495", "A61K 31/425", "C07D 417/12", "A61P 25/00", "A61K 31/496", "A61P 25/02" ]

4,559

420,889,503

2014-02-14

51,297,842

N

This disclosure is in the area of medical diagnostics that provides a method to assist in diagnosis and monitoring the progression of Alzheimer's disease and mild cognitive impairment (MCI).

en

Screening Blood for Protein Biomarkers and Uses Thereof in Alzheimer's Disease and Mild Cognitive Impairment

5332080_US

48480379_US

G01N 33/6896,G01N2333/4709,G01N2333/4737,G01N2333/51,G01N2333/5403,G01N2333/5428,G01N2333/5434,G01N2333/5437,G01N2333/5443,G01N2333/58,G01N2333/70564,G01N2333/775,G01N2800/2821,G01N2800/50,G01N2800/52

[ "G01N 33/543" ]

88,001

52,896,688

1985-02-26

6,229,403

Y

A membrane of substantially non-crosslinked organic polymers which contain ionogenic groups bonded to the polymer chain via an alkylene radical, at intervals of not less than 4 carbon atoms.

en

Membranes of substantially non-crosslinked organic polymers which contain bonded ionogenic groups

5240549_DE

5263304_DE,5423474_DE

B01D 71/82,C08J 5/2218

[ "C08J 5/22", "C25B 13/08", "C08G 85/00", "C08F 8/00", "B01D 71/82", "B01J 47/12" ]

44,889

15,624,399

2002-05-27

23,133,363

Y

An impact-resistant primer coating composition comprising: - at least one non-hydrophilic acrylate monomer; - at least one epoxy monomer; and - at least one photoactivable cationic catalyst.

en

EPOXY/ACRYLATE BASED PRIMER COATING COMPOSITIONS AND THEIR USE IN THE OPTICAL FIELD.

12537361_US,5542774_FR,25595687_US,13096588_US

12537361_US,13096588_US,25595687_US

C08F 283/10,C08L2312/00,C09D 4/00,C09D 133/068,C09D 151/08,Y10S 525/937,Y10T 428/31504,Y10T 428/31507,Y10T 428/31511,Y10T 428/31533,Y10T 428/31551

[ "C09D 4/02", "C08F 283/10", "C09D 7/12", "C09D 4/00", "C09D 163/00", "C09D 133/06", "C09D 151/08", "C09D 5/00" ]

11,912

30,125,161

1997-06-04

15,301,600

N

A receptor type tyrosine kinase-like protein having an Eph family-like structure and seemingly showing dominant negative (variant being dominant) or signal modification and/or amplification.

en

NOVEL HUMAN RECEPTOR TYPE TYROSINE KINASE-LIKE PROTEIN

13367758_JP,5357769_JP

13367758_JP

A61K 38/00,C07K 14/705,C07K 14/71,C12N 9/1205

[ "C12N 9/12", "C12N 15/12", "C07K 14/705", "C07K 14/71", "A61K 38/00" ]

24,596

456,166,593

2014-03-17

55,961,471

Y

The present invention relates to methods and systems for electronic countermeasures, and particularly to methods and systems for electronic countermeasures that employ radar jamming devices.

en

Passive listening pulse adaptive sidelobe canceller

11012464_US

52588718_US,52683685_US,52649413_US

G01S 7/36,H04K 3/20,H04K 3/228,H04K 3/825,H04K2203/32

[ "H04K 3/00", "G01S 7/36" ]

101,133

53,945,415

1992-05-01

27,414,543

Y

This invention describes the preparation and use of anticonvulsant agents. In particular, triazolopyridine compounds are described which have utility in the treatment of epilepsy in mammals.

en

Pharmaceutically active triazolopyridine compounds

5327265_US

6196288_US

C07D 471/04

[ "C07D 471/04" ]

47,625

42,199,383

2000-09-15

10,861,009

N

An isolate peptide having an amino acid sequence of at least 5 amino acids identical to a portion of amino acids 333-355 of the Hepreceptor for example: MREKEELMLRLQDY(p)EEKTKKAERELSEQIQRALQ

en

Regulatory/unfolding peptides of ezrin

13906407_

25811067_

A61K 38/00,A61P 31/00,A61P 31/12,A61P 31/18,A61P 35/00,A61P 37/00,C07K 14/005,C07K 14/4713,C07K 14/705,C12N2740/16122

[ "C07K 14/16", "C07K 7/08", "C07K 7/06", "A61P 35/00", "A61K 38/00", "C07K 14/705", "C07K 14/47", "A61P 31/18", "A61P 31/00", "A61K 38/17" ]

28,051

16,809,185

1990-03-13

23,327,270

Y

A composition containing a polymeric material obtained by interreacting an epoxy-novolak polymer with an organosilicon compound, a radiation sensitive onium salt, and a near U.V. sensitizer.

en

Negative photoresist and use thereof.

11589_US

2875948_US,2875947_US,2537914_US

G03F 7/0758

[ "H01L 21/027", "G03F 7/038", "G03F 7/075", "H01L 21/30", "C08G 59/00", "G03F 7/029", "C08G 59/18", "C08G 59/14", "G03F 7/004" ]

17,866

23,688,589

2004-09-06

29,226,495

N

The present invention relates to a method of measuring pain in an individual, by calculating the percentage ratio of one neurotransmitter to one or more other neurotransmitters, in a sample.

en

TEST

29236681_GB

G01N 33/94,G01N 33/942

[ "G01N 33/94" ]

23,012

560,608,395

2021-05-06

78,411,918

N

Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.

en

METHODS OF IMPROVING AUTONOMIC IMBALANCE OR SYMPATHETIC IMPAIRMENT BY REGULATING THE STELLATE GANGLION

79707691_US

81834914_US,81910480_US,81825383_US,79620567_US

A61B 18/14,A61B 90/37,A61B2090/378,A61K 9/0019,A61K 31/167,A61K 31/445,A61K 31/573,A61M 16/022,A61M2202/0208,A61M2210/10,A61N 1/05,A61N 5/0622,A61N 7/02,A61N 7/022,A61N2005/0612,A61N2005/0626,A61N2005/073,A61N2007/0021,A61N2007/003,A61N2007/025,A61P 11/00

[ "A61M 16/00" ]

159,756

46,930,194

2008-03-31

39,795,480

Y

The present invention is drawn to treatment of neuropathic pain due to spinal cord injury. In this regard, the present invention discloses methods and composition to treat neuropathic pain.

en

Treatment for neuropathic pain due to spinal cord injury

5979303_US,5264897_US

5979303_US

A61K 31/7052,A61P 29/00

[ "A61K 31/7052", "A61P 29/00", "C12N 15/11" ]

32,930

50,735,858

1989-10-04

26,942,177

Y

A method of electromyographic scanning paravertebral muscles comprising measuring electrical potential across a persons's spinous process bilaterally across segments of the spinous process.

en

Paraspinal electromyography scanning

8045188_US

8045189_US

A61B 5/389

[ "A61B 5/0488" ]

40,600

47,833,812

1993-09-14

8,204,767

Y

The invention relates to the use of p-chloro-N-(2-morpholinoethyl)benzamide in the treatment of anxiety disorders, such as, panic disorders, social phobia and obsessive compulsive disorder,

en

Treatment of anxiety disorders

6280496_CH,6280495_BR

6280498_CH,6280497_BR

A61K 31/535,A61P 25/18,A61P 25/22

[ "A61P 25/18", "C07D 295/12", "A61P 25/22", "A61K 31/5375", "A61K 31/535" ]

36,402

501,675,244

2018-05-18

57,145,011

Y

In another aspect the invention provides the method for supporting of neurological state assessment and neurological rehabilitation, especially within cognitive and/or speech dysfunctions.

en

System and method for supporting of neurological state assessment and for supporting neurological rehabilitation, especially within cognitive and/or speech dysfunction

77840900_PL,77868943_PL

74790434_PL,74680705_PL

A61B 3/113,A61B 3/14,A61B 5/0062,A61B 5/16,A61B 5/163,A61B 5/486,A61B 5/741,A61B 5/7415,A61B 5/7435,A61B 5/7445,A61M 21/00,A61M2021/0027,A61M2021/005,A61M2205/3303,A61M2205/3313,A61M2205/52,G06F 3/04883,G09B 19/04,G10L 13/00,H04N 5/2253,H04N 5/2256,H04N 5/33

[ "A61B 5/00", "A61B 3/14", "H04N 5/33", "G06F 3/0488", "G09B 19/04", "A61M 21/00", "A61B 5/16", "A61B 3/113", "G10L 13/04", "H04N 5/225" ]

121,679

545,068,189

2020-01-02

74,259,533

N

The disclosure relates to systems, methods and programs for geometrically constrained, unsupervised training of convolutional autoencoders on unlabeled images for extracting eye landmarks.

en

GEOMETRICALLY CONSTRAINED, UNSUPERVISED TRAINING OF CONVOLUTIONAL AUTOENCODERS FOR EXTRACTION OF EYE LANDMARKS

79554212_IL

79576162_IL,79650319_IL,79549313_IL,79593309_IL,79673782_US,79720763_IL

G06K 9/6259,G06N 3/04,G06N 3/0454,G06N 3/08,G06N 3/084,G06N 3/088,G06T 7/11,G06T2207/20081,G06T2207/20084,G06T2207/20132,G06V 10/755,G06V 10/82,G06V 40/165,G06V 40/171,G06V 40/19,G06V 40/193

[ "G06T 7/11", "G06N 3/04", "G06N 3/08", "G06K 9/62", "G06K 9/00" ]

149,571

55,223,393

2008-10-14

39,970,874

N

Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3- dimethyiphenyl)ethyl)-1 H-imidazole-2(3H)-thione.

en

TREATMENT OF SENSORIMOTOR DISORDERS WITH 4- ( 1- ( 2, 3 -DIMETHYLPHENYL) ETHYL) -1H-IMIDAZ0LE-2 ( 3H) -THIONE

40162048_US,12475122_US,12475121_US,5763799_US

12475121_US,40162048_US,12475122_US

A61K 31/4174,A61P 1/06,A61P 25/00,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/30,A61P 25/36

[ "A61P 25/18", "A61P 25/16", "A61P 1/06", "A61P 25/24", "A61K 31/4174", "A61P 25/22", "A61P 25/14" ]

52,853

273,396,593

2006-12-04

35,685,952

N

A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent.

en

Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders

8843796_GB,11187447_GB

11187447_GB,8843796_GB

C12Q 1/6883,C12Q2600/158,G01N 33/505,G01N 33/6896,G01N2800/30,G01N2800/52

[ "C12Q 1/68", "C12Q 1/48", "C12Q 1/02" ]

58,877

469,291,507

2016-03-04

56,879,570

N

Cholesterol and desmosterol levels, and the ratio of these levels can be used as a blood biomarker for Alzheimer's disease, frontotemporal lobar degeneration, or dementia with Lewy bodies.

en

BIOMARKER OF DEMENTIA WITH LEWY BODIES

1371538_JP,4165062_JP

55756971_JP,55690493_JP,55701809_JP,55689012_JP

G01N 33/50,G01N 33/92,G01N2800/2814,G01N2800/52

[ "G01N 33/50", "G01N 33/92" ]

103,513

41,139,079

2007-09-28

36,498,804

Y

Kompozicija, apimanti (i) aromatinio poliesterio derva ir (ii) polidiena, kur daugiau negu 20 moliu procentu mineto polidieno mer vienetu turi 1,2 mikrostruktura arba jo hidrinta liekana.

en

DEGUONI SUGERIANTYS POLIESTERIAI SU PRISLOPINTOMIS PAKARTOTINIO PANAUDOJIMO SPALVOMIS

12473441_US

16941990_US,12473444_US,12473442_US

C08C 19/02,C08C 19/44,C08K 5/098,C08L 9/00,C08L 15/00,C08L 19/00,C08L 19/006,C08L 21/00,C08L 53/02,C08L 67/02

[ "C08L 9/00", "C08K 5/00", "C08G 81/00", "C08L 67/00", "C08L 53/00" ]

26,923

522,630,271

2019-05-23

68,613,797

N

Provided herein are methods related to the evaluation of treatment efficacy for neurological disorders. Also provided are methods for evaluating the progression of neurological disorders.

en

METHODS FOR EVALUATION OF TREATMENT AND PROGRESSION OF NEUROLOGICAL DISORDERS

70105132_US

72363999_US

A61K 31/198,A61K 45/06,A61K 49/0004

[ "A61K 49/00" ]

134,240

570,591,113

2021-05-21

78,707,645

N

The present disclosure provides novel gene therapy constructs comprising a PARK2 gene or activating variant and methods of administering to treat Parkinson's Disease or symptoms thereof.

en

GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE

83646797_US

48468815_US

A61K 48/0058,A61K 48/0075,A61P 25/00,C12N 9/104,C12N 15/86,C12N2750/14143,C12Y 203/02

[ "A61K 48/00" ]

165,056

352,599,054

2011-09-29

45,870,889

N

The present invention relates to the use of TNF-α for the treatment of a pain and/or a urinary tract symptom(s) associated with Cronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).

en

Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome

11789145_US

A61K2039/54,A61K2039/545,A61P 13/00,A61P 13/08,A61P 25/00,C07K 16/241,C07K2317/76

[ "A61K 39/395", "A61P 13/08", "A61P 25/00" ]

72,841

50,107,234

1982-03-25

26,924,545

Y

Neuroleptically active cycloalka[4,5]pyrrolo[2,3-g]isoquinolines of the formula <IMAGE> A wherein n, R1, R2 and X are as hereinafter set forth, and intermediates therefore are described.

en

Cycloalka[4,5]pyrrolo[2,3-g]isoquinolines

5244394_US

5278373_US,5259436_US

C07D 209/88,C07D 217/04,C07D 471/04

[ "C07D 209/88", "C07D 217/04", "C07D 471/04" ]

39,591

421,097,057

2012-10-15

48,082,779

N

A method of treating a psychiatric or cognitive developmental disorder in a subject, includes administering to the subject a therapeutically effective amount of at least one RXR agonist.

en

RXR AGONIST COMPOUNDS AND METHODS

5233209_US

11265606_US

A61K 9/0014,A61K 31/192,A61K 31/426,A61K 31/433,A61K 31/4418,A61K 31/4436,A61K 45/06,A61P 25/00,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28

[ "A61K 45/06", "A61K 31/4418", "A61K 31/192" ]

88,110

25,475,157

2001-10-31

18,816,639

N

A gene containing a polynucleotide which encodes the amino acid sequence represented by SEQ ID NO:1; and the polynucleotide encoded by this gene. This is a schizophrenia-associated gene.

en

PCA2501 GENE

27872355_JP,12600858_JP,30544466_JP,15431097_JP,27872356_JP

30544466_JP,12600858_JP,27872355_JP,27872356_JP

C07K 14/47

[ "C12N 15/12", "C07K 14/47" ]

24,152

329,268,864

2010-05-17

42,610,065

Y

The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.

en

Methods of treating urogenital-neurological disorders using galanin retargeted endopeptidases

11571851_US,5273163_US,5608081_US

11571851_US,5608081_US

A61K 38/4893,A61K 47/6415,A61P 13/00,A61P 13/08,A61P 13/10,A61P 15/00,A61P 25/00

[ "A61P 13/00", "A61P 13/08", "A61K 38/48", "A61P 13/10", "C12N 9/96", "C07K 14/00", "C12N 9/00", "A61P 25/00", "A61P 15/00" ]

65,169

298,710,234

2009-10-05

43,857,053

Y

A method for administering nerve growth factor to treat cravings is provided. Pharmaceutical compositions for the treatment of cravings comprising nerve growth factor are also provided.

en

Method of treating cravings by administration of nerve growth factor

7594243_US,12456027_US

7594243_US

A61K 38/185,A61P 1/10,A61P 3/00,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36,A61P 43/00

[ "A61P 43/00", "A61K 38/18" ]

61,371

51,143,225

1974-05-17

27,427,885

Y

Compounds of the formulas WHEREIN R1, R2, R3, R4, R5, R6, m and n and X are as hereinafter set forth, ARE DESCRIBED. The compounds of formulas I and Ia are useful as neuroleptic agents.

en

Dibenzo {8 b,f{9 thiepins bearing piperazinyl substitution

5244394_US

6502347_CH,5295726_CH,8311421_CH

C07D 409/14

[ "C07D 409/14" ]

41,376

574,626,822

2021-11-02

56,895,047

N

The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

en

Anti-Axl Antagonistic Antibodies

55863587_NO,50059101_NO

79635124_NO,79633243_NO,55878807_NO,54692349_NO,12125511_NO,12244288_NO

A61K 45/06,A61K 47/6801,A61K2039/505,A61P 35/00,A61P 35/02,A61P 35/04,A61P 43/00,C07K 16/2863,C07K 16/32,C07K 16/40,C07K2317/24,C07K2317/33,C07K2317/41,C07K2317/76,C07K2317/92,C07K2319/55,G01N 33/573,G01N 33/574,G01N 33/6893,G01N2333/912,G01N2800/7052

[ "C07K 16/28", "A61P 35/00", "A61K 45/06", "A61K 47/68" ]

166,960

567,933,946

2019-10-29

80,442,651

Y

A system which can implement an electronic version of pai gow poker using an electronic gaming system, as well as a physical pai gow game played with physical cards on a physical table.

en

Casino wagering system

72414939_US

54767028_US

G07F 17/3241,G07F 17/3246,G07F 17/3293

[ "G07F 17/32", "G06F 17/00" ]

163,773

48,554,608

2002-07-12

26,890,086

N

A method and method for measuring emotional and cognitive responses to advertising and other forms of communication through the use of facial electromyographic techniques is described.

en

Continuous emotional response analysis with facial EMG

38258122_,38258123_

38258125_US,38258124_US

A61B 5/16,A61B 5/389,A61B 5/6824

[ "A61B 5/16", "A61B 5/0488" ]

37,377

540,542,709

2020-05-07

73,050,887

N

The disclosure provides methods of making and systems comprising a brain organoid operably connected to a controlled device such that the brain organoid controls the controlled device.

en

BRAIN ORGANOID MACHINE INTERFACE

5439802_US

42274766_US

C12M 35/02,C12N 5/0618,C12N2500/38,C12N2501/11,C12N2501/115,C12N2501/13,C12N2501/727,C12N2503/04,C12N2506/02,C12N2506/45,C12N2513/00,C12N2533/90

[ "C12N 5/071", "C12N 5/0793", "G01N 33/50" ]

146,658

53,452,036

1977-04-13

27,260,186

Y

Thieno[1,5]benzodiazepines having useful CNS activity containing the novel tricyclic ring system: <IMAGE> the 10-position being substituted by an amino, preferably a piperazino, group.

en

Thieno-benzodiazepines

5335192_GB

6766189_GB,6257242_GB

C07C 323/00,C07D 333/38,C07D 333/68,Y10T 428/28,Y10T 428/31815

[ "C07D 333/38", "C07D 495/04", "C07D 333/68" ]

46,114

4,436,249

1993-04-21

11,363,050

N

Aminoalcohols N-acyl derivatives useful in the prevention and in the treatment of human and animal pathologies induced by mast cell degranulation following to a peripheral nerve noxa.

en

AMINOALCOHOLS-N-ACYLDERIVATIVES AS THERAPEUTICAL AGENTS AGAINST THE NEUROGENIC ENDONEURAL OEDEMA DEVELOPING AT THE PERIPHERAL NERVE

16405250_IT

13337807_IT,12983509_IT,12983510_IT

A61K 31/16,A61P 25/02

[ "A61P 25/02", "A61K 31/165", "A61K 31/381", "A61K 31/16", "A61K 9/20", "C07D 339/04", "A61K 31/385", "C07D 333/22", "C07C 233/18", "C07C 233/24", "A61K 31/60" ]

4,511

549,327,076

2020-10-22

75,491,947

N

Provided are compositions and methods for detecting and modulating oscillatory patterns within the basolateral amygdala (BLA) for diagnosis and treatment of anxiety related disorders.

en

Compositions and Methods for Treatment of Post-Traumatic Stress Disorder using Closed-Loop Neuromodulation

5211659_US

79713388_US,79680932_US

A61B 5/0006,A61B 5/165,A61B 5/37,A61B 5/374,A61B 5/378,A61B 5/383,A61B 5/4088,A61B 5/4836,A61B 5/7253,A61B2562/0219,A61B2562/0271,A61B2562/029,A61B2576/026,A61N 1/0534,A61N 1/36089,A61N 1/36096,A61N 1/36139,A61N 1/36189,G06F 3/015,G16H 10/20,G16H 20/30,G16H 20/70,G16H 50/20

[ "A61N 1/05", "A61N 1/36" ]

152,309

444,312,702

2015-03-13

50,278,731

Y

Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.

en

Reversible chemoenzymatic labeling of native and fusion carrier protein motifs

5211659_US

51483092_US,51492264_US,8382655_US

C07F 9/65616,C07K 14/195,C07K 14/37,C07K 19/00,C07K2319/00,C07K2319/21,C07K2319/24,C07K2319/60,C12P 21/06,G01N 33/68,G01N2333/245

[ "C07F 9/6561", "C07K 14/37", "G01N 33/68", "C12P 21/06", "C07K 14/195", "C07K 19/00" ]

95,642

545,289,856

2020-07-16

74,343,719

N

A system and method comprising a noninvasive framework utilizing electroencephalography (EEG) to achieve the neural control of a robotic device for continuous random target tracking.

en

Methods and Systems for Noninvasive Mind-Controlled Devices

5210963_US

79683824_US,79692169_US,79714031_US,79584052_US

A61B 5/245,A61B 5/316,A61B 5/369,A61B 5/7264,A61F 2/72,G05B 19/409,G05B2219/36133,G06F 3/015,G09B 5/02,G09B 19/00,G16H 40/67,G16H 50/20,G16H 50/50

[ "G05B 19/409", "A61B 5/00", "G09B 19/00" ]

149,736

365,447,729

2011-09-23

45,874,425

N

The invention provides novel tricyclic compounds of Formula I' that inhibit β -secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

en

Compounds for treating neurodegenerative diseases

12503500_US

16716228_US,16844918_US,40434602_US

A61K 31/4188,A61P 25/00,A61P 25/28,C07D 491/107,C07D 491/20

[ "C07D 491/147", "C07D 491/12", "A61K 31/352" ]

74,998

4,546,843

1995-08-14

27,403,950

N

The present invention provides the use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the treatment of anxiety and related disorders.

en

COMPOSITION AND METHOD FOR TREATING ANXIETY

5363504_US

13532451_US,5966506_US,13406344_US,16509917_US,16482671_US

A61K 31/00,A61K 31/198,A61K 31/215,A61P 25/20,A61P 25/22,A61P 43/00,C07C 62/38,C07C 229/50,C07C2602/18,C07D 235/02,Y10S 514/811,Y10S 514/82

[ "A61K 31/198", "C07C 229/50", "A61K 45/00", "C07C 62/38", "A61K 31/215", "A61P 43/00", "C07D 235/02", "A61P 25/20", "A61K 31/195", "A61K 31/00", "A61K 31/19" ]

5,158

4,516,007

1994-07-19

22,259,870

N

Transgenic mice with a human interleukin 1.beta. gene is provided. The transgenic mice may be used to evaluate compounds affecting Alzheimer's Disease and other cognitive disorders.

en

TRANSGENIC ANIMAL MODEL FOR COGNITIVE DISORDERS

5329402_US

16494521_US,16494523_US,13476727_US,16309577_US,16494524_US,16494522_US

A01K 67/0278,A01K2207/15,A01K2217/00,A01K2217/05,A01K2217/20,A01K2227/105,A01K2267/03,A01K2267/0318,A01K2267/0368,C07K 14/545,C12N 15/8509,C12N2830/008

[ "C12N 15/09", "C12P 21/02", "C07K 14/545", "C12N 5/10", "A01K 67/027", "C12N 15/85" ]

4,950

48,160,430

2005-06-07

32,732,343

Y

That deep brain stimulation can be used in the treatment of movement disorders and for identifying an area of the brain to be targeted by DBS in the treatment of movement disorders.

en

Deep brain stimulation of the zona incerta

6457781_US,6218536_GB

6218536_GB

A61N 1/36067,A61N 1/36082

[ "A61N 1/18", "A61N 1/00", "A61N 1/36" ]

36,765

4,571,173

1996-04-18

23,673,720

N

The invention provides a method for treating a dyskinesias comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno¢2,3-b!¢1,5! benzodiazepine.

en

METHOD FOR TREATING DYSKINESIAS

5363504_US

16546026_US

A61K 31/551,A61P 25/02,A61P 25/14,A61P 25/20

[ "A61K 31/551", "A61K 31/55", "A61P 25/20", "A61P 25/02", "C07D 409/04" ]

5,328

520,956,671

2019-04-24

68,238,004

N

A digital image capturing and processing system and method having a plurality of intertwined processing planes for the efficient processing of information associated with an image.

en

Reconfigurable 3D Pixel-Parallel Neuromorphic Architecture for Smart Image Sensor

8433808_US

72404599_US,54706683_US,72353722_US,72364079_US

G06V 10/44,G06V 10/94,G06V 10/955,H04N 5/23229,H04N 5/378

[ "G06K 9/00", "G06K 9/46", "H04N 5/232" ]

133,092

25,488,415

2002-10-29

19,146,074

N

A protease specific to ubiquitin occurring in the brain which is useful in studying the molecular mechanism of the expression neuroplasticity and so on and a DNA encoding the same.

en

UBIQUITIN-SPECIFIC PROTEASE OCCURRING IN THE BRAIN AND DNA ENCODING THE SAME

5816899_JP,30551877_JP,10344330_JP

30551877_JP,10344330_JP

C07K 16/40,C12N 9/6472

[ "C07K 16/40", "C12N 15/55", "C12N 15/12", "C12N 9/64" ]

24,263

365,965,228

2012-08-09

46,717,941

N

This disclosure describes a novel compounds and pharmaceutical compositions for inhibiting the TRPAl ion channel and/or medical conditions related to TRPAl, such as pain or asthma.

en

INHIBITING TRANSIENT RECEPTOR POTENTIAL ION CHANNEL TRPA1

43915561_US,16791187_US,16536628_US,16635782_US,16813127_US,12998616_US,12569439_US,16930107_US,43915562_US,16901125_US

16536628_US,43915561_US,16813127_US,16635782_US,12569439_US,43915562_US,16930107_US,16791187_US

A61P 11/06,A61P 25/00,A61P 25/04,A61P 29/00,A61P 43/00,C07D 473/08

[ "A61K 31/52", "C07D 473/08", "A61P 25/04" ]

75,505

499,697,032

2018-04-17

54,360,941

Y

The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

en

Pyridine or pyrimidine derivatives

48393455_US

6647657_CH,56827109_CH

A61K 31/444,A61K 31/506,A61P 25/18,C07D 211/80,C07D 239/24,C07D 401/04,C07D 401/14

[ "C07D 239/24", "C07D 401/14", "A61K 31/506", "A61K 31/444", "C07D 401/04", "C07D 211/80", "A61P 25/18" ]

120,699

16,889,834

1991-02-28

26,296,748

N

A class of spirocyclic piperidine derivatives are selective ligands at sigma recognition sites and are therefore useful in the treatment and/or prevention of psychiatric disorders.

en

SPIROCYCLIC ANTIPSYCHOTIC AGENTS

212218_GB

3035347_GB,3028788_FR

A61K 31/36,A61K 31/445,A61P 25/18,C07D 221/20,C07D 401/06,C07D 405/06

[ "A61K 31/36", "A61P 25/18", "C07D 221/20", "C07D 405/06", "C07D 401/06", "A61K 31/445" ]

18,091

503,809,306

2018-07-30

55,275,018

Y

The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

en

Pyrazol-pyridine derivatives

48393455_US

56827109_CH,6647657_CH

A61P 25/00,A61P 25/18,A61P 43/00,C07D 401/04,C07D 409/14

[ "C07D 401/04", "C07D 409/14" ]

122,998

53,592,451

1977-06-30

25,107,765

Y

The beta -endorphin analog beta -endorphin (6-31), although lacking the enkephalin moiety i.e., beta -endorphin (1-5) exhibits analgesic activity which is not reversed by naloxone.

en

{62 -Endorphin analog

5244394_US

9421651_US

A61P 25/04,C07K 14/6755,Y10S 514/809

[ "A61P 25/04", "A61K 38/00", "C07K 14/575", "C07K 14/675", "C07K 14/655" ]

46,532

4,419,450

1992-09-25

25,078,150

N

X-8651 K This invention provides N-alkyl-3-phenyl-3- (2-substituted phenoxy)propylamines which are useful to treat neurological disorders associated with norepinephrine imbalance.

en

N-ALKYL-3-PHENYL-3-(2-HALO-SUBSTITUTED PHENOXY) PRN-ALKYL-3-PHENYL-3-(2-HALO-SUBSTITUTED PHENOXY) PROPYLAMINES OPYLAMINES

16260890_US

16189343_US,16394255_US,16189342_US

A61K 31/135,A61P 1/00,A61P 13/00,A61P 13/02,A61P 15/00,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/26,A61P 25/28,A61P 25/30,A61P 39/02,C07C 217/48,C07C 323/20,C07C 323/29

[ "C07C 319/20", "A61P 15/00", "C07C 217/48", "A61P 25/18", "C07C 323/32", "C07C 323/20", "A61P 13/02", "A61P 39/02", "A61P 25/26", "A61K 31/085", "A61P 25/22", "A61P 25/20", "A61P 13/00", "A61P 25/30", "A61K 31/135", "A61P 25/28", "A61P 1/00", "A61P 25/24" ]

4,423

15,955,026

2002-06-03

8,177,622

Y

The initial status, final status and action performed by user are collected as learning samples which are used for deriving and initializing target action to be performed by user.

en

MAN-MACHINE INTERFACE UNIT CONTROL METHOD; ROBOT APPARATUS; AND ITS ACTION CONTROL METHOD

49843067_JP,15554_DE

49148130_DE,49150369_DE,49185169_DE,49220106_JP,49211311_JP,49585397_JP,49650549_JP

B62D 57/02,B62D 57/032,G05B 13/0265,G05B 19/042

[ "B62D 57/02", "A63H 11/00", "B62D 57/032", "G05B 19/042", "G05B 13/02" ]

14,272

15,944,733

2002-02-05

23,016,078

Y

This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.

en

USE OF QUETIAPINE FOR THE TREATMENT OF COCAINE DEPENDENCE

5864_SE

1286744_US

A61K 31/554,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36

[ "A61K 31/554", "A61P 25/34", "A61P 25/32", "A61P 25/36", "A61P 25/30", "C07D 281/16" ]

14,139

53,963,636

1997-06-24

26,717,449

Y

A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.

en

Method for treating Meniere's disease

6331289_US

6229446_US,5267045_US,10343578_US,10343579_US

A61K 31/55

[ "A61K 31/55" ]

47,677

16,373,462

2006-12-05

37,904,362

N

The invention encompasses 2-(N-methyl-propanamine)-3-(2-naphthol) thiophene, a duloxetine hydrochloride impurity, as well as its use as a reference marker and reference standard.

en

2-(N-METHYL-PROPANAMINE)-3-(2-NAPHTOL) THIOPHENE, AN IMPUTITY OF DULOXETINE HYDROCHLORIDE

8477_IL

2108721_IL,2128115_IL,146982_IL,2128113_IL,2128114_IL,2128116_IL

A61P 13/00,A61P 25/24,A61P 29/00,C07D 333/20

[ "A61P 25/24", "A61P 29/00", "A61K 31/38", "C07D 307/52", "A61P 13/00" ]

17,122

16,730,901

1988-08-11

22,203,256

N

Certain amino-2-hydroxypropyloximinoheterocycles are beta -adrenoceptor antagonists useful in the treatment of elevated intraocular pressure, hypertension, angina and arrhythmia.

en

AMINO-2-HYDROXYPROPYLOXIMINO-HETEROCYCLE BETA BLOCKERS

11493_US

2731791_US,2479310_US,2257034_US,2257033_US,2731792_US

A61P 9/12,A61P 25/02,A61P 27/02,A61P 27/06,C07D 333/36,C07D 335/02,C07D 339/00

[ "A61K 31/38", "C07C 251/58", "A61P 27/06", "C07D 495/04", "C07D 337/04", "C07D 335/02", "C07D 333/38", "C07D 495/10", "A61K 31/15", "A61P 27/02", "C07D 333/36", "C07C 67/00", "A61K 31/215", "A61P 9/12", "C07D 339/00", "A61K 31/381", "C07C 239/00", "A61K 31/382", "A61P 25/02", "A61K 31/385" ]

17,701

56,454,987

2006-05-17

37,533,259

N

The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker.

en

METHOD FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE.

11372958_ES

40440769_,40440768_,16913546_ES,40440765_,40440766_,40440767_

C07K 14/4711,C07K 14/705,C12Q 1/6883,C12Q2545/114,C12Q2600/112,C12Q2600/158,G01N 33/50,G01N 33/53,G01N 33/5308,G01N 33/6896,G01N2800/2821

[ "C07K 14/705" ]

54,489

52,005,965

1975-06-05

26,413,683

Y

3-[2-(4-PHENYL-1-PIPERAZINYL)ETHYL]-4H-pyrido[1,2-a]pyrimidin-4-one derivatives have central nervous depressant and hypotensive activities and are useful as major tranquillizers.

en

Pyrido{8 1,2-a{9 pyrimidinone derivatives

5244603_JP

8992928_JP,5933253_JP,7561438_JP,6122567_JP

C07D 471/04

[ "C07D 471/04" ]

43,248

55,425,972

2008-06-04

40,089,060

Y

Apparatus and method for delivering audible, electrical or mechanical tones having a specific characteristic to a human vestibular system to achieve thereby a therapeutic result.

en

Neuromuscular therapeutic device

10815674_US,10815672_US,10815673_US,10815671_US

10815674_US,10815673_US,10815672_US

A61N 1/36036

[ "A61N 1/00", "A61H 1/00" ]

53,197

52,034,934

1984-03-13

26,992,223

Y

A pulmonary training method for persons having COPD involving daily exercise by inhaling through a restricted opening with inspirative resistance less than that producing stress.

en

Pulmonary training method

9016150_US

9016151_US

A63B 23/18

[ "A63B 23/18" ]

43,304

4,747,904

2000-08-01

16,717,834

N

Remedies for neurogenic pains comprising an mGluR1 receptor antagonist for systemic administration. Thus, drugs efficacious in treating various neurogenic pains can be provided.

en

PHARMACEUTICALS FOR NEUROPATHIC PAIN

7329924_JP

13126974_JP,16703972_JP,16703973_JP,13126975_JP,9610565_JP

A61K 31/00,A61K 31/429,A61P 25/00

[ "A61K 31/429", "A61K 31/00", "A61P 25/00" ]

7,138

52,836,790

1976-06-18

24,532,742

Y

N-(4-aminophenyl)-aromatic dicarboximides, e.g. those of the formula <IMAGE> R = alkyl, (hydroxy, alkoxy or alkanolyloxy)-alkyl R' = chloro OR SALTS THEREOF ARE ANTICONVULSANTS.

en

Aromatic dicarboximides

5232729_US

9564250_US,5436061_US

C07D 209/48,C07D 217/24,C07D 307/89,C07D 333/38,C07D 471/04,Y10S 514/96

[ "C07D 209/48", "C07D 217/24", "C07D 333/38", "C07D 307/89", "C07D 471/04" ]

44,777

474,746,084

2015-06-12

54,934,605

Y

The disclosure provides methods of detecting and monitoring brain injury in a test subject comprising analyzing a blood sample from the test subject for increased levels of PrP

en

Methods and kits for detecting brain injury

8044048_CA

53846426_

A61B 5/150022,A61B 5/15003,A61K 39/0007,C07K 14/47,G01N 33/6893,G01N 33/6896,G01N2333/47,G01N2333/70596,G01N2800/28,G01N2800/2828,G01N2800/40,G01N2800/56

[ "G01N 33/53", "C07K 14/47", "A61B 5/15" ]

106,502

45,633,003

2001-10-05

26,931,920

N

Bile-acid conjugates useful for sustained release of L-DOPA, inhibitors of catechol O-methyl transferase and/or inhibitors of L-aromatic amino acid decarboxylase are provided.

en

BILE ACID PRODRUGS OF L-DOPA AND THEIR USE IN THE SUSTAINED TREATMENT OF PARKINSONISM

12474189_US,37049520_US,12491874_US,12614443_US

37049520_US,12614443_US,12491874_US

A61K 38/00,A61K 47/554,A61K 47/64,A61K 47/65,C07K 5/0205

[ "A61K 38/00", "A61K 47/48", "C07K 5/02" ]

30,381

518,721,580

2019-05-20

40,789,289

Y

System and methods related to wagering, such as slot machines and/or other electronic games. Some wagering may relate to market indicators, market lines, and/or stop commands.

en

System and method for slot machine game associated with financial market indicators

5436255_US

70117834_US,72351974_US

G07F 17/32,G07F 17/3227,G07F 17/3244,G07F 17/3262,G07F 17/34

[ "A63F 13/00", "G07F 17/32", "G07F 17/34" ]

131,263

219,970

2003-11-24

32,392,528

Y

The invention provides a waterborne epoxy corrosion resistant primer comprising a waterborne epoxy, a curing agent, and a non-chromate containing corrosion-inhibiting pigment.

en

Chromate free waterborne epoxy corrosion resistant primer

11080_US

339573_US

C09D 5/08,C09D 5/084,C09D 163/00

[ "C09D 5/08", "C09D 7/12", "C09D 163/00", "C09D 5/02", "C09D 163/02", "C09D 5/00", "C09D 177/00" ]

1,207

413,397,189

2011-11-04

46,025,134

N

The present invention relates to a cell-based model useful for identifying molecules that modify intracellular pathways of alpha-synuclein and tau aggregation and degradation.

en

Cell-Based Models of Neurodegenerative Disease

12289087_US,45367273_US,11160493_US,5223267_US,45367275_US,45367274_US,7082996_US

12289087_US,7082996_US,45367274_US,45367275_US,11160493_US,45367273_US

G01N 33/5058,G01N 33/6896

[ "G01N 33/68", "G01N 33/50" ]

83,827

53,446,976

2007-04-11

38,520,579

Y

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor

en

Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders

5223604_US

8484525_US,5823321_US,8484527_US,8484524_US

A61P 25/00,A61P 25/28,C07D 491/06

[ "C07D 498/04", "A61K 31/538", "A61K 31/5365", "C07D 491/04" ]

46,097

52,785,391

1976-05-26

25,693,196

Y

(+)-(S)-enantiomer of 3-{2-[4-(8-fluoro-10,11-dihydro-2-methyldibenzo[b,f]thiepin-10-yl)-1-p iperazinyl]-ethyl} -2-oxazolidinone, active as a neuroleptic agent, is described.

en

({30 )-(S)-Enantiomer of 3-{55 2-{8 4-(8-fluoro-10,11-dihydro-2-methyl-dibenzo{8 b,f{9 thiepin-10-yl)-1-piperazinyl{9 -ethyl{56 -2-oxazolidinone

5746081_US

5295726_CH

A61K 31/38,C07C 323/00,C07D 337/14

[ "C07D 413/14", "C07D 409/14", "C07D 413/12", "A61K 31/38", "C07D 403/14", "A61K 31/55", "C07D 337/14" ]

44,683

53,354,402

2004-02-03

33,423,057

N

Computerized training apparatus which combines electroencephalograph (EEG) based biofeedback attention training with behavior modification support, coaching support, or both.

en

Systems and methods for behavioral modification and behavioral task training integrated with biofeedback and cognitive skills training

39508482_US

39508483_US,39508484_US,39508485_US

A61B 5/375,G06Q 50/20,G09B 7/02

[ "G06F 17/00", "G06F 15/18", "G06N 5/02", "G06N 5/04" ]

45,866

58,123,712

2007-11-09

39,364,112

N

A hetero-dimeric or hetero-oligomeric receptor, comprising at least one t hyrotropin releasing hormone receptor subunit associated with at least one o rexin receptor subunit.

en

THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS

15085685_AU

40902669_AU,40902668_AU,40902666_AU,40902667_AU

A61P 3/04,A61P 25/00,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28,A61P 43/00,G01N 33/542

[ "C07K 14/72", "G01N 33/566", "A61K 38/22", "C07K 16/28", "G01N 33/74", "G01N 33/78" ]

57,254

53,997,202

1997-07-03

10,796,408

Y

This invention relates to a method of electron spin resonance enhanced magnetic resonance imaging which relies on ex vivo dynamic nuclear polarisation of an MR imaging agent.

en

Nuclear Polarization Enhanced Nuclear Magnetic Resonance Imaaging

5294754_NO,10371320_FI

5969477_DK,5588699_DK,8857106_SE,5601508_SE,10371322_SE,7761484_FI,10371321_GB

G01R 33/282,G01R 33/5601,G01R 33/62

[ "G01N 24/12", "B82B 1/00", "A61B 5/055", "G01R 33/62", "G01R 33/28" ]

47,777

527,281,819

2019-09-05

69,641,779

N

The present disclosure provides methods for diagnosing and determining the disease progression of neurodegenerative disorders in patients using neurophysiological biomarkers.

en

Neurophysiological Biomarkers for Neurodegenerative Disorders

5219515_US

74752170_US,74798571_US

A61B 5/316,A61B 5/389,A61B 5/4082,A61B 5/4088,A61B 5/4842,A61B 5/6824

[ "A61B 5/00", "A61B 5/0488", "A61B 5/04" ]

137,616

45,722,783

2003-11-20

32,329,181

N

Transcranial magnetic stimulation is interleaved with functional brain imaging to examine cortex sensitivity and brain communication and to determine efficacy of medication.

en

METHODS AND SYSTEMS FOR USING TRANSCRANIAL MAGNETIC STIMULATION AND FUNCTIONAL BRAIN MAPPING FOR EXAMINING CORTICAL SENSITIVITY, BRAIN COMMUNICATION, AND EFFECTS OF MEDICATION

37112672_US,37131631_US,10242514_US,37112671_US

37131631_US,37112672_US,37112671_US

G01R 33/4806,G01R 33/4808

[ "A61B 5/055", "G01R 33/48", "A61B" ]

31,869

52,823,299

1985-01-28

10,113,358

Y

Benzodiazepines of formula <IMAGE> wherein R3 is methyl or ethyl and R4 is chlorine or fluorine are useful therapeutic agents for the treatment of neuropsychic disturbances.

en

Method of treating neuropsychic disturbances by benzodiazepine derivatives and composition therefor

5271897_FR

5246427_FR,8271048_FR

A61P 21/02,A61P 25/00,A61P 25/08,A61P 25/20,A61P 25/26,C07D 243/24

[ "A61K 31/55", "A61P 25/08", "A61K 31/551", "A61K 31/5513", "A61K 31/495", "C07D 243/18", "C07D 243/16", "C07D 243/24", "C07D 243/28", "C07D 243/26", "A61P 25/26", "A61P 21/02", "A61P 25/20", "A61P 25/00" ]

44,750

51,943,561

1984-02-02

27,045,759

Y

4-Hydroxy-N-[5-[(substituted hetero)methyl]-3-isoxazolyl]-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides as agents for treating pain in mammals resulting from inflammation.

en

3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides

5233822_US

6210171_US,5471439_US

C07D 261/14,C07D 261/18,C07D 417/12

[ "C07D 261/14", "C07D 417/12", "C07D 261/18" ]

43,098

449,584,270

2014-03-14

51,538,346

Y

EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.

en

EGFR-binding modular recognition domains

12178422_US

9649388_US,11958076_US,10546187_US,7163384_US

A61K 38/00,A61K 45/06,A61K2039/505,A61P 29/00,A61P 35/00,C07K 7/08,C07K 14/435,C07K 16/18,C07K 16/24,C07K 16/28,C07K 16/2848,C07K 16/2863,C07K 16/32,C07K 16/40,C07K2317/31,C07K2317/35,C07K2317/76,C07K2319/00,C12N 9/0002,Y02A 50/30

[ "A61K 38/10", "C07K 16/32", "A61K 39/00", "C07K 16/40", "A61K 45/06", "C07K 7/08", "C07K 19/00", "C12N 9/00", "C07K 16/28", "A61K 38/00", "A61K 39/395", "C07K 16/24", "C07K 14/435", "C07K 16/18" ]

99,174

53,298,596

1977-01-24

24,558,317

Y

Novel 1-hydroxy-3-alkyl-6,7,8,9,10,11-hexahydrodibenz[b,d]oxepins are prepared from cyclohexenyl resorcinol derivatives and are useful as central nervous system depressants.

en

Cyclohexenyl resorcinol derivatives

5255150_US

6314162_US

C07C 39/23,C07C2601/16,C07D 313/10

[ "C07D 313/10", "C07C 39/23" ]

45,719

537,914,188

2020-03-11

70,155,381

N

A method of treating CNS tumors such as gliomas is provided comprising delivering a β-emitting radionuclide containing composition to the tumor via the cerebral vasculature.

en

TREATMENT OF CNS TUMORS

5505141_GB,5218813_US

77886481_US,11572052_US,52622076_US

A61K 9/0019,A61K 51/1251,A61K 51/1255,A61K2121/00,A61P 35/00

[ "A61P 35/00", "A61K 51/12", "A61K 9/00" ]

144,728

274,180,594

2007-08-31

39,157,768

N

Compounds of formula (I). Selectively inhibit production of Abeta(1-42) and hence find use in treatment of diseases associated with deposition of beta-amyloid in the brain.

en

DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS

9090002_US,11250469_US,9090009_US,11250468_US,9090010_US

11250468_US,9090009_US,9090010_US,9090002_US,11250469_US

A61P 25/28,C07D 211/38

[ "C07D 211/38", "A61K 31/445" ]

59,817

450,862,951

2015-09-25

55,583,340

N

Disclosed are compounds, compositions and methods for stopping seizures, including status epilepticus, and are useful for the treatment and prevention of seizure disorders.

en

METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING

5292546_US

6098141_US

A61K 31/05,A61K 31/16,A61K 45/06

[ "A61K 45/06", "A61K 31/05" ]

100,117

420,198,802

2012-07-27

46,581,998

N

A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.

en

COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD1 MAYTANSINOID IMMUNOCONJUGATE AND RITUZIMAB

5271897_FR

47183502_FR,47209462_FR,47283087_FR

A61K 31/537,A61K 39/3955,A61K 39/39558,A61K 47/6803,A61K 47/6849,A61K2039/507,A61P 35/00,A61P 35/02,C07K 16/2803,C07K 16/2887

[ "A61K 47/48", "A61K 39/395", "A61K 31/537" ]

87,506

52,147,844

1996-02-20

32,045,695

Y

A method of making antibodies to hirudin by immunizing with an immunogenic composition containing polymerized hirudin monomers in the absence of carrier protein is taught.

en

Anti-hirudin polyclonal antibodies and their use for the identification, immunopurification and quantitative determination of hirudin

5245423_IT

9103748_IT,7926710_IT,5861859_IT,9103747_IT,9103746_IT

C07K 14/815,C07K 16/38,Y10S 530/855

[ "C07K 16/38", "C07K 14/815" ]

43,534

340,493,256

2011-07-01

45,400,192

N

A chiral synthesis of pyrrolidine compounds en route to seletive neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.

en

CHIRAL SYNTHESIS OF PYRROLIDINE CORE COMPOUNDS EN ROUTE TO NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

12579331_US,43351681_US,5279165_US

43351681_US,12579331_US

C07D 401/06,C07D 401/12,C07D 493/08

[ "C07B 55/00", "C07D 401/14", "C07D 401/06" ]

71,525

16,682,779

1987-06-23

25,376,501

N

Cyclic and bridged cyclic somatostatin analogs have been found to be effective in the treatment of peripherally mediated pain and are therefore useful as analgesic agents.

en

CYCLIC AND BRIDGED CYCLIC SOMATOSTATIN ANALOGS USEFUL AS ANALGESIC AGENTS

11493_US

2645541_US,2645542_US,2378892_US

A61K 38/31,A61P 25/04

[ "C07K 14/655", "A61K 38/00", "A61K 38/31", "A61K 38/04", "C07K 7/06", "A61P 25/04", "C07K 7/64", "C07K 14/575" ]

17,591

4,031,236

1976-02-17

24,285,695

Y

TRIAZOLOCYCLOALKYLTHIADIAZINE DE,RIVATIVES Novel triazolocycloalkylthiadiazines, their preparation, and use as antisecretory agents and central nervous system depressants.

en

TRIAZOLOCYCLOALKYLTHIADIAZINE DERIVATIVES

15820088_

15832060_

C07D 249/12,C07D 513/04

[ "C07D 513/04", "C07D 249/12", "C07D 249/14" ]

3,280

46,305,165

2005-01-27

35,461,012

Y

Novel BNP variants. The novel BNP variants according to the present invention may optionally be used for diagnosis of a BNP variant-detectable disease as described herein.

en

Brain natriuretic peptide spliced variant

5671065_IL

5671071_GB,5671068_IL,5671072_IL,5671069_IL,5671067_IL,5671070_IL,5671066_IL

G01N 33/74,G01N2800/321,G01N2800/325

[ "G01N 33/53", "C07K 14/705", "C07K 14/435", "G01N 33/74", "A61K 38/17" ]

32,415

53,758,754

1977-10-14

27,172,028

Y

Novel thienotriazolodiazepine derivatives and processes for their preparation are described. These compounds are useful as anticonvulsants, muscle-relaxants and sedatives.

en

Thienotriazolodiazepine derivatives

5244394_US

8632746_AT,5594795_CH,6089165_AT,8469920_CH

C07D 333/36,C07D 495/04,C07D 495/14,Y10S 514/906,Y10S 514/937,Y10S 514/962,Y10S 514/966

[ "C07D 495/04", "C07D 333/36", "C07D 495/14" ]

47,021

337,451,960

2011-04-01

44,079,474

Y

Novel polymorphic forms and salts of 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.

en

Polymorphs and salts

11887758_IT,5859336_IT,11887759_IT,5859335_IT,5219543_IT

11887759_IT,11887758_IT,5859335_IT,5859336_IT

A61K 9/0053,A61K 31/19,A61K 31/192,A61P 25/28,C07B2200/13,C07C 61/40,C07C 229/26,C07C 279/14,C07C2601/02

[ "A61K 31/192", "A61P 25/28", "C07C 61/40" ]

69,801

458,815,708

2014-08-19

52,484,110

N

The invention relates to methods of detecting a genetic variation in a genetic sample from a subject using labeled probes and counting the number of labels in the probes.

en

Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

60040665_

69285340_,60435032_,63193519_,58426412_

C12Q 1/6809,C12Q 1/6825,C12Q 1/6827,C12Q 1/6837,C12Q 1/6876,C12Q2600/156,C12Q2600/158,C12Q2600/16

[ "G01N 33/53" ]

102,602